<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">92775</article-id>
<article-id pub-id-type="doi">10.7554/eLife.92775</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92775.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2801-6202</contrib-id>
<name>
<surname>Lee</surname>
<given-names>Selene Seoyun</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Civitelli</surname>
<given-names>Livia</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3392-8564</contrib-id>
<name>
<surname>Parkkinen</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Nuffield Department of Clinical Neurosciences, Oxford Parkinsons’ Disease Center, University of Oxford</institution>, <country>UK</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Mistry</surname>
<given-names>Pramod</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Yale University</institution>
</institution-wrap>
<city>New Haven</city>
<country>United States of America</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Mistry</surname>
<given-names>Pramod</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>Yale University</institution>
</institution-wrap>
<city>New Haven</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label><bold>For correspondence:</bold> <email>livia.civitelli@ndcn.ox.ac.uk</email>; <email>laura.parkkinen@ndcn.ox.ac.uk</email></corresp>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-03-21">
<day>21</day>
<month>03</month>
<year>2024</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP92775</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-09-28">
<day>28</day>
<month>09</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-10-06">
<day>06</day>
<month>10</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.04.560803"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Lee et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Lee et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-92775-v1.pdf"/>
<abstract>
<title>Abstract</title>
<p>The alpha-synuclein (<italic>α</italic>Syn) seeding amplification assay (SAA) that allows the generation of disease-specific in vitro seeded fibrils (SAA fibrils) is used as a research tool to study the connection between the structure of <italic>α</italic>Syn fibrils, cellular seeding/spreading, and the clinico-pathological manifestations of different synucleinopathies. However, structural differences between human brain-derived and SAA <italic>α</italic>Syn fibrils have been recently highlighted. Here, we characterize biophysical properties of the human brain-derived <italic>α</italic>Syn fibrils from the brains of patients with Parkinson’s disease with and without dementia (PD, PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and compare them to the ‘model’ SAA fibrils. We report that the brain-derived <italic>α</italic>Syn fibrils show distinct biochemical profiles, which were not replicated in the corresponding SAA fibrils. Furthermore, the brain-derived <italic>α</italic>Syn fibrils from all synucleinopathies displayed a mixture of ‘straight’ and ‘twisted’ microscopic structures. However, the PD, PDD, and DLB SAA fibrils had a ‘straight’ structure, whereas MSA SAA fibrils showed a ‘twisted’ structure. Finally, the brain-derived <italic>α</italic>Syn fibrils from all four synucleinopathies were phosphorylated (S129). However, the phosphorylation pattern was not maintained in the SAA fibrils, where only PDD and DLB SAA fibrils showed weak signs of phosphorylation. Our findings demonstrate the limitation of the SAA fibrils modelling the brain-derived <italic>α</italic>Syn fibrils and pay attention to the necessity of deepening the understanding of the SAA fibrillation methodology.</p>
</abstract>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Synucleinopathies are all characterized by abnormal accumulation of the protein alpha-synuclein (<italic>α</italic>Syn) in the brain. However, they are clinically and neuropathologically highly heterogeneous diseases with prominent disease-specific differences in presentation of symptoms, rate of disease progression, and the brain regions and cell types that are vulnerable to <italic>α</italic>Syn deposition and neuronal death. In Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), and dementia with Lewy bodies (DLB), <italic>α</italic>Syn aggregation is found in the neuronal soma as Lewy bodies (LBs) and in the axons and dendrites as Lewy neurites (LNs) (<xref ref-type="fig" rid="fig1">Figure <bold>1</bold></xref>) (<bold><italic><xref ref-type="bibr" rid="c9">Forno, 1988</xref>; <xref ref-type="bibr" rid="c40">Spillantini et al., 1997</xref>; <xref ref-type="bibr" rid="c6">Braak et al., 2003</xref></italic></bold>). Furthermore, the astroglial accumulation of <italic>α</italic>Syn is a prominent but so far underdiagnosed pathology in these Lewy body disorders (<bold><italic><xref ref-type="bibr" rid="c1">Altay et al., 2022</xref></italic></bold>). The <italic>α</italic>Syn pathology in multiple system atrophy (MSA) is primarily found in oligodendrocytes as glial cytoplasmic inclusions (GCIs) (<bold><italic><xref ref-type="bibr" rid="c28">Papp et al., 1989</xref></italic></bold>).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Distinct <italic>α</italic>Syn strains are associated with different neuropathological and clinical hallmarks of PD, DLB, and MSA.</title>
<p><italic>α</italic>Syn misfolds and aggregates into fibrils with characteristic conformations. At the atomic level, PD and DLB strains share a “Lewy fold” structure at the fibrillar core and comprise a single protofilament (<bold><italic><xref ref-type="bibr" rid="c52">Yang et al., 2022</xref></italic></bold>). MSA strains are twisted with two protofilaments intertwined, forming a different core structure to the “Lewy fold” (<bold><italic><xref ref-type="bibr" rid="c35">Schweighauser et al., 2020</xref></italic></bold>). At a cellular level, PD is characterized by significant neuronal loss at the brainstem, especially substantia nigra (SN), highlighted in blue. Lewy body (LB) and Lewy neurite (LN) accumulate in neurons. <italic>α</italic>Syn also accumulates in astrocytes, forming astroglial pathology. In DLB, the brainstem and neocortex are the most affected regions, highlighted in green. Here, LB and LN accumulate in neurons and astroglial pathology is also observed. In MSA, the cerebellum, basal ganglia and brainstem are the most affected, highlighted in red. Here, <italic>α</italic>Syn accumulates as glial cytoplasmic inclusions (GCIs) in the oligodendrocytes. The 3D structures of the <italic>α</italic>Syn fibrillar cores were generated using PyMOL, and the PDB structures from <bold><italic><xref ref-type="bibr" rid="c35">Schweighauser et al. (2020)</xref>; <xref ref-type="bibr" rid="c52">Yang et al. (2022</xref></italic></bold>).</p></caption>
<graphic xlink:href="560803v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The mechanistic link between <italic>α</italic>Syn and clinico-pathological diversity of the synucleinopathies is hypothesized to be the different fibrillar ‘strains’ of <italic>α</italic>Syn in analogy to prion disease. A strain is generated when <italic>α</italic>Syn monomers fold into specific fibrillar forms with distinct conformational and bio-logical characteristics (<bold><italic><xref ref-type="bibr" rid="c27">Melki, 2017</xref></italic></bold>). Under the disease condition, misfolded and aggregated <italic>α</italic>Syn recruits normal, soluble endogenous <italic>α</italic>Syn to aggregate, and this self-perpetuating process spreads throughout the brain-periphery axis. Several studies have generated <italic>α</italic>Syn fibrils in vitro using various experimental conditions to characterize the presence of different strains (<bold><italic><xref ref-type="bibr" rid="c5">Bousset et al., 2013</xref>; <xref ref-type="bibr" rid="c29">Peelaerts et al., 2015</xref>; <xref ref-type="bibr" rid="c22">Li et al., 2018</xref>; <xref ref-type="bibr" rid="c13">Guerrero-Ferreira et al., 2019</xref>; <xref ref-type="bibr" rid="c19">Lau et al., 2020</xref></italic></bold>), but their relevance to human condition remains questionable. However, some studies have also examined <italic>α</italic>Syn fibrils extracted from the human brain tissue of different synucleinopathies and these have demonstrated that the human-derived <italic>α</italic>Syn strains exhibit distinct structures (<bold><italic><xref ref-type="bibr" rid="c35">Schweighauser et al., 2020</xref></italic></bold>), infectivity and bioactivity in cells (<bold><italic><xref ref-type="bibr" rid="c46">Woerman et al., 2018a</xref>, <xref ref-type="bibr" rid="c48">2019</xref>; <xref ref-type="bibr" rid="c2">Ayers et al., 2022</xref></italic></bold>) and animals (<bold><italic><xref ref-type="bibr" rid="c32">Prusiner et al., 2015</xref>; <xref ref-type="bibr" rid="c19">Lau et al., 2020</xref>; <xref ref-type="bibr" rid="c16">Holec et al., 2022</xref>; <xref ref-type="bibr" rid="c30">Peng et al., 2018</xref></italic></bold>). The intrinsic structure of <italic>α</italic>Syn proteoforms may also depend on the local conditions of the brain region where they are formed and thus may vary within a single disease entity (<bold><italic><xref ref-type="bibr" rid="c30">Peng et al., 2018</xref>; <xref ref-type="bibr" rid="c19">Lau et al., 2020</xref>; <xref ref-type="bibr" rid="c35">Schweighauser et al., 2020</xref></italic></bold>). Future studies must comprehensively map the distinct fingerprints of human brain-derived <italic>α</italic>Syn strains to the disease.</p>
<p>Seeding amplification assays (SAAs) have become more applicable due to their feasibility in amplifying in vitro-seeded <italic>α</italic>Syn fibrils (SAA fibrils) from human biosamples. The SAA reaction incorporates a key characteristic of pathological <italic>α</italic>Syn, which is its ability to induce aggregation of monomeric <italic>α</italic>Syn into different complex conformers. This ‘seeding’ property is the critical mechanism of SAA. When pathological <italic>α</italic>Syn is present in the biosample, it seeds aggregation of the recombinant <italic>α</italic>Syn in the reaction, which is monitored in real-time using a fluorophore such as Thioflavin-T (ThT). SAA, together with different biosamples such as cerebrospinal fluid (CSF) (<bold><italic><xref ref-type="bibr" rid="c8">Fairfoul et al., 2016</xref>; <xref ref-type="bibr" rid="c31">Poggiolini et al., 2021</xref></italic></bold>), brain homogenates (<bold><italic><xref ref-type="bibr" rid="c12">Groveman et al., 2018</xref>; <xref ref-type="bibr" rid="c34">Sano et al., 2018</xref></italic></bold>), and skin punctures (<bold><italic><xref ref-type="bibr" rid="c25">Mammana et al., 2020</xref>; <xref ref-type="bibr" rid="c18">Kuzkina et al., 2021</xref></italic></bold>), has presented its potential as a diagnostic method but also as a research tool to amplify disease-relevant fibrils. The newly amplified SAA fibrils are assumed to encode the intrinsic properties of the original seeding fibrils, thus being representative of the disease-specific strains. Therefore, using the ‘model’ SAA fibrils, studies have shown disease-specific structural, biochemical and phenotypic differences, suggesting the presence of distinct conformational <italic>α</italic>Syn strains in different synucleinopathies (<bold><italic><xref ref-type="bibr" rid="c41">Strohaker et al., 2019</xref>; <xref ref-type="bibr" rid="c36">Shahnawaz et al., 2020</xref>; <xref ref-type="bibr" rid="c44">Van der Perren et al., 2020</xref>; <xref ref-type="bibr" rid="c10">Frieg et al., 2022</xref></italic></bold>). Recent studies have, however, demonstrated significant differences between the human brain-derived and SAA fibrils in their structure (<bold><italic><xref ref-type="bibr" rid="c23">Lövestam et al., 2021</xref></italic></bold>) and seeded pathology in vivo (<bold><italic><xref ref-type="bibr" rid="c44">Van der Perren et al., 2020</xref></italic></bold>). Nevertheless, there is currently a limited understanding of whether the resulting SAA fibrils truly preserve the original properties of the seeding fibrils across all the major synucleinopathies.</p>
<p>Here, we aim to investigate the biophysical differences between 1) the brain-derived <italic>α</italic>Syn fibrils in different synucleinopathies and 2) the brain-derived <italic>α</italic>Syn versus the corresponding SAA fibrils. We examine the brain-derived <italic>α</italic>Syn fibrils extracted from the brains of patients with PD, PDD, DLB, and MSA and the brain-derived versus SAA <italic>α</italic>Syn fibrils and show striking differences in their biochemical profile, structure, and phosphorylation pattern. Our findings reveal further evidence supporting the molecular diversity among <italic>α</italic>Syn fibrils from different synucleinopathies. Also, our study highlights the limitations of the SAA fibrils to fully mirror the brain-derived <italic>α</italic>Syn fibrils and the need to study further the mechanism of seeding amplification and the application of SAA fibrils.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Detection of differential <italic>α</italic>Syn seeding activity from brain-derived fibrils of PD, PDD, DLB, and MSA</title>
<p>We extracted <italic>α</italic>Syn fibrils from the human brain of patients with PD (<italic>n</italic> = 3), PDD (<italic>n</italic> = 3), DLB (<italic>n</italic> = 3), MSA (<italic>n</italic> = 3) and healthy controls (<italic>n</italic> = 3) (<xref ref-type="table" rid="tblS1">Table S1</xref>). The entorhinal cortex was used for PD, PDD, and DLB, and the striatum for MSA, as these are one of the main affected regions with <italic>α</italic>Syn pathology in each disorder. The brain-derived fibrils were diluted 1: 1,000 and used as a seed in an SAA reaction to generate in vitro amplified fibrils (SAA fibrils). PD, PDD, DLB, and MSA brain-derived <italic>α</italic>Syn fibrils reached the maximum ThT fluorescence within 100 h (<xref ref-type="fig" rid="fig2">Figure <bold>2</bold> A</xref>). The healthy controls did not display seeding potential (<xref ref-type="fig" rid="figS1">Figure <bold>S1</bold></xref>), except for case 2 (HC 2), which showed an increasing signal towards the end of the reaction (approximately 91 h). The unseeded recombinant <italic>α</italic>Syn remained negative in all reactions. Kinetic parameters revealed a statistical difference in the seeding activities between PD/MSA and PDD/DLB. Kinetic parameters revealed a statistical difference in the seeding activities between PD/MSA and PDD/DLB. The time to reach 50 % of the maximum fluorescence (<italic>T</italic><sub>50</sub>) and the lag phase (time to reach five standard deviations of the minimum fluorescence) were significantly lower in PDD/DLB than in PD/MSA (<xref ref-type="fig" rid="fig2">Figure <bold>2</bold>B,C</xref>). As a result, the area under the curve (AUC) was statistically higher in PDD/DLB than in PD/MSA (<xref ref-type="fig" rid="fig2">Figure <bold>2</bold>D</xref>). However, the maximum rate of increase in fluorescence (<italic>V</italic><sub>MAX</sub>) was not statistically different among the diseases (<xref ref-type="fig" rid="fig2">Figure <bold>2</bold>E</xref>). Overall, the SAA kinetic parameters suggest PDD and DLB brain-derived <italic>α</italic>Syn fibrils have a more aggressive seeding capacity than PD and MSA.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><title><italic>α</italic>Syn SAA seeded with <italic>α</italic>Syn fibrils from PD, PDD, DLB, and MSA brains.</title>
<p>(<bold>A</bold>) SAA was performed with sarkosyl insoluble <italic>α</italic>Syn fibrils extracted from PD (<italic>n</italic> = 3), PDD (<italic>n</italic> = 3), DLB (<italic>n</italic> = 3), and MSA (<italic>n</italic> = 3) brains. The curves represent an average of six replicates. (<bold>B</bold>) Time to reach 50% of the maximum fluorescence (<italic>T</italic><sub>50</sub>). (<bold>C</bold>) The lag phase was taken at the time point where each positive reaction exceeded the threshold (RFU ≥ 5 SD). (<bold>D</bold>) Area under the curve (AUC). (<bold>E</bold>) The largest increase of fluorescence per unit of time (V<sub>MAX</sub>). (<bold>B-E</bold>) Plotted values represent the six replicates of the three cases for each disease (<italic>N</italic> = 18). RFU, relative fluorescence unit; SD, standard deviation. *<italic>P</italic> ≤ 0.05, **<italic>P</italic> ≤ 0.01, ***<italic>P</italic> ≤ 0.005</p></caption>
<graphic xlink:href="560803v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2b">
<title>Brain-derived and SAA <italic>α</italic>Syn fibrils display distinct biochemical profiles</title>
<p>At the end of the SAA reaction, the SAA <italic>α</italic>Syn fibrils were collected by ultracentrifugation. Having established that prion strains can be characterized by distinct biochemical profiles (<bold><italic><xref ref-type="bibr" rid="c19">Lau et al., 2020</xref>; <xref ref-type="bibr" rid="c36">Shahnawaz et al., 2020</xref>; <xref ref-type="bibr" rid="c33">Sano et al., 2014</xref></italic></bold>), we examined this characteristic in the brain-derived and SAA <italic>α</italic>Syn fibrils. First, the fibrils were denatured with increasing concentrations of guanidine hydrochloride (GdnHCl, 0-5 M) and then digested with proteinase-K (PK, 1 µg/ml).</p>
<p>The weakest GdnHCl (1 M) treatment completely denatured the PD and MSA brain-derived <italic>α</italic>Syn fibrils, as they were no longer visible on the immunoblot (<xref ref-type="fig" rid="fig3">Figure <bold>3</bold></xref>). This result was consistent among all the three cases analyzed (<xref ref-type="fig" rid="figS2">Figure <bold>S2</bold></xref>). Higher GdnHCl concentrations of 2 M and 3 M denatured PDD and DLB brain-derived <italic>α</italic>Syn fibrils, respectively (<xref ref-type="fig" rid="fig3">Figure <bold>3</bold></xref>). The results illustrate that PD and MSA brain-derived <italic>α</italic>Syn fibrils have weaker biochemical stability than PDD and DLB fibrils.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Brain-derived and SAA <italic>α</italic>Syn fibrils exhibited distinct biochemical profiles.</title>
<p>Brain-derived and SAA <italic>α</italic>Syn fibrils were subjected to denaturation with increasing concentration of GdnHCl (0-5 M) and to PK digestion (1 µg/ml). The antibody clone 42 (BD Biosciences) was used to reveal the PK-resistant peptides. Immunoblots of one representative case from PD, PDD, DLB, and MSA are presented. The brain-derived and SAA fibrils are on the top and bottom rows, respectively. The molecular weights of the protein standards are shown in kilodaltons (kDa). Black arrows mark the five PK-resistant peptides revealed in the SAA fibrils. SAA, seeding amplification assay; GndHCl, guanidine-hydrochloride; PK, proteinase-K.</p></caption>
<graphic xlink:href="560803v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The disappearance of the bands on the immunoblot after GndHCl treatment limited the comparative study of the <italic>α</italic>Syn fibrils between synucleinopathies. Therefore, we repeated the experiment using PK alone to improve the visualization of the biochemical profiles. The brain-derived <italic>α</italic>Syn fibrils were treated with five different PK concentrations starting from 0 mg/ml, incrementing to 1 mg/ml. PD cases contained mostly monomeric <italic>α</italic>Syn (15 kDa) that immediately degraded at the lowest PK concentration (1 ug/ml) (<xref ref-type="fig" rid="fig4">Figure <bold>4</bold>A</xref>). In contrast, in PDD, DLB, and MSA cases, high molecular weight (MW) bands above 15 kDa were observed, indicative of <italic>α</italic>Syn aggregates (<xref ref-type="fig" rid="fig4">Figure <bold>4</bold>B-D</xref>). Furthermore, lower MW bands (13, 10, 7 kDa) were also observed. As the PK concentration increased, the PDD and DLB fibrils gradually degraded, as the high MW bands started to disappear and low MW bands below 15 kDa began to appear (<xref ref-type="fig" rid="fig4">Figure <bold>4</bold>B,C</xref>). Similarly, the MSA fibrils gradually degraded as the PK concentration increased (<xref ref-type="fig" rid="fig4">Figure <bold>4</bold>D</xref>). However, low MW bands below 15 kDa were less prominent than those of PDD and DLB.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Proteinase-K degradation patterns of the brain-derived <italic>α</italic>Syn fibrils.</title>
<p>The brain-derived <italic>α</italic>Syn fibrils from (<bold>A</bold>) PD, (<bold>B</bold>) PDD, (<bold>C</bold>) DLB, and (<bold>D</bold>) MSA were subjected to increasing concentrations of PK at 0, 0.001, 0.01, 0.1, and 1 mg/ml, represented by the escalating triangular bar. Western blot was performed using the antibody clone 42 (BD Biosciences). The molecular weights of the protein standards are shown in kilodaltons (kDa).</p></caption>
<graphic xlink:href="560803v1_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Although we experimented with an identical amount of total protein (10 ug), the amount of <italic>α</italic>Syn fibril could differ in each brain-derived sample. Using immunohistochemistry, we observed a lower load of <italic>α</italic>Syn pathology in PD and MSA brains than in PDD and DLB (<xref ref-type="fig" rid="figS3">Figure <bold>S3</bold></xref>). In addition, the brain-derived fibrils were immunogold-labelled with anti-p<italic>α</italic>Syn and negatively stained for transmission electron microscopy (TEM). The samples were imaged with TEM at low magnification to observe <italic>α</italic>Syn fibril density and distribution. PD and MSA cases contained 1-3 <italic>α</italic>Syn fibrils per region of interest (ROI), whereas PDD and DLB cases contained 3-5 <italic>α</italic>Syn fibrils per ROI (<xref ref-type="fig" rid="figS4">Figure <bold>S4</bold></xref>). Adjacent slot blots also confirmed a higher amount of <italic>α</italic>Syn fibrils in PDD and DLB than in PD and MSA brain-derived samples. Therefore, lower fibril concentration in the PD and MSA brains could have limited the observation of the PK-resistant peptides using immunoblotting.</p>
<p>The SAA fibrils revealed markedly different biochemical profiles to the brain-derived <italic>α</italic>Syn fibrils. We observed identical profiles among all SAA fibrils from PD, PDD, DLB, and MSA. PK-resistant bands of 7 and 10 kDa started to appear after treatment with 2 M GdnHCl (<xref ref-type="fig" rid="fig3">Figure <bold>3</bold></xref>). However, with increasing concentrations of GdnHCl, specific PK-resistant peptides appeared, consisting of five bands (7, 11, 12, 13, 14 kDa) (<xref ref-type="fig" rid="fig3">Figure <bold>3</bold></xref>). These findings suggest that harsher denaturing conditions are required to destabilize the SAA fibrils and expose PK digestion sites. We concluded that SAA <italic>α</italic>Syn fibrils are more stable and characterized by distinct biochemical properties than the brain-derived <italic>α</italic>Syn fibrils.</p>
</sec>
<sec id="s2c">
<title>Brain-derived and SAA <italic>α</italic>yn fibrils show structural differences</title>
<p>Next, we used TEM to investigate the structure of the brain-derived and SAA <italic>α</italic>Syn fibrils. The brain-derived <italic>α</italic>Syn fibrils from PD, PDD, and DLB exhibited two structures in TEM: straight and twisted (<xref ref-type="fig" rid="fig5">Figure <bold>5</bold>A</xref>, <xref ref-type="fig" rid="figS5">Figure <bold>S5</bold></xref>). The fibrils from MSA were predominantly straight, with the rare presence of twisted type. Therefore, we only considered straight fibrils when comparing the dimensions of the fibrils among synucleinopathies. The length of the fibrils from different synucle-inopathies ranged between 68 to 885 nm. Only the PDD fibrils were significantly longer than DLB and MSA (<xref ref-type="fig" rid="fig5">Figure <bold>5</bold>B</xref>). The width ranged from 7 to 21 nm, and there were significant differences between the diseases. PD had the widest fibrils, followed by MSA/DLB and PDD (<xref ref-type="fig" rid="fig5">Figure <bold>5</bold>C</xref>).</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Transmission electron microscopy revealed different structures of brain-derived and SAA <italic>α</italic>Syn fibrils.</title>
<p>(<bold>A</bold>) Electron microscope image of negatively stained brain-derived (BD) and SAA fibrils from PD, PDD, DLB, and MSA brains. (<bold>B</bold>,<bold>C</bold>) The lengths and widths of brain-derived fibrils. (<bold>D</bold>,<bold>E</bold>) The lengths and width of SAA fibrils. MSA SAA fibrils were twisted with alternating widths, resulting in two clusters of measurements. A total of 30 fibrils from each case were measured and plotted (<italic>N</italic> = 90). Scale bar = 50 nm. *<italic>P</italic> ≤ 0.05, **<italic>P</italic> ≤ 0.01, **** <italic>P</italic> ≤ 0.001.</p></caption>
<graphic xlink:href="560803v1_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>On the other hand, the SAA fibrils demonstrated a single dominant structure. PD, PDD, and DLB SAA fibrils were all straight, and MSA SAA fibrils were all twisted (<xref ref-type="fig" rid="fig5">Figure <bold>5</bold>A</xref>). Unlike the brain-derived fibrils, the SAA fibrils were highly clustered. The length of the SAA fibrils ranged from 104 to 1008 nm, and PDD/DLB SAA fibrils were significantly longer than those of PD/MSA (<xref ref-type="fig" rid="fig5">Figure <bold>5</bold>D</xref>). The width ranged from 8 to 25 nm, and the widths of the MSA SAA fibrils were distributed into two groups due to the alternating widths arising from the twisted structure. Unlike the brain-derived fibrils, the average widths of the SAA fibrils were similar between different synucleinopathies (<xref ref-type="fig" rid="fig5">Figure <bold>5</bold>E</xref>).</p>
<p>Overall, in DLB, the SAA fibrils were significantly longer and wider than the brain-derived fibrils (<xref ref-type="fig" rid="figS6">Figure <bold>S6</bold></xref>). SAA fibrils from PDD were wider than the brain-derived fibrils but not different in length. The dimensions of the brain-derived and SAA fibrils from PD and MSA were not significantly different. However, it was difficult to compare the dimensions of the MSA fibrils as the brain-derived and SAA fibrils had different morphologies. Our observations demonstrate that brain-derived and SAA <italic>α</italic>Syn fibrils exhibit distinct TEM structures.</p>
</sec>
<sec id="s2d">
<title>Brain-derived and SAA <italic>α</italic>Syn fibrils have distinct phosphorylation patterns</title>
<p>To confirm the identity of the fibrils imaged by TEM, we used immunogold with <italic>α</italic>Syn fibril conformation specific (MJFR-14) and pS129-specific (anti-p<italic>α</italic>Syn) antibodies. Both brain-derived and SAA fibrils from all four synucleinopathies were probed with MJFR-14, confirming that the fibrils were <italic>α</italic>Syn fibrils (<xref ref-type="fig" rid="fig6">Figure <bold>6</bold>A</xref>). The brain-derived fibrils were also strongly labeled with anti-p<italic>α</italic>Syn. MJFR-14 and anti-p<italic>α</italic>Syn, however, did not label the twisted brain-derived fibrils from PD, PDD, and DLB (<xref ref-type="fig" rid="fig6">Figure <bold>6</bold>B</xref>). The SAA fibrils from PD and MSA were not labeled with anti-p<italic>α</italic>Syn, but PD and MSA SAA fibrils were weakly labeled (<xref ref-type="fig" rid="fig6">Figure <bold>6</bold>A</xref>).</p>
<fig id="fig6" position="float" fig-type="figure">
<label>Figure 6.</label>
<caption><title>Brain-derived and SAA <italic>α</italic>Syn fibrils showed distinct phosphorylation patterns.</title>
<p>(<bold>A</bold>) Electron microscope image of brain-derived and SAA <italic>α</italic>Syn fibrils from PD, PDD, DLB, and MSA brains labeled with fibril conformation-specific (MJFR-14) and anti-p<italic>α</italic>Syn (pS129) antibodies. (<bold>B</bold>) The twisted <italic>α</italic>Syn fibrils from PD, PDD, and DLB brains were not labeled for MJFR-14 and pS129. Scale bar = 50 nm. (<bold>C</bold>,<bold>D</bold>) Semi-quantification of <italic>α</italic>Syn fibrils and p<italic>α</italic>Syn confirm the different patterns of <italic>α</italic>Syn phosphorylation between brain-derived and SAA <italic>α</italic>Syn fibrils. The amount of <italic>α</italic>Syn fibrils and p<italic>α</italic>Syn in (<bold>C</bold>) brain-derived and (<bold>D</bold>) SAA fibrils was determined using a slot blot. Two µg of proteins were filtered on a nitrocellulose membrane and probed with MJFR-14 and pS129 antibodies. The semi-quantitative measurement was done by averaging the measurements of three cases from each disease. Error bars indicate ± one standard deviation (SD). * <italic>P</italic> ≤ 0.05.</p></caption>
<graphic xlink:href="560803v1_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>We performed a slot blot using identical antibodies to confirm the immunogold-labelling results. On the slot blot, DLB brain-derived <italic>α</italic>Syn fibrils showed the strongest signal with MJFR-14 and anti-p<italic>α</italic>Syn, followed by PDD, MSA, and PD (<xref ref-type="fig" rid="fig6">Figure <bold>6</bold>C</xref>). Interestingly, the anti-p<italic>α</italic>Syn signal from the SAA fibrils was markedly different from the brain-derived fibrils. In parallel to the anti-p<italic>α</italic>Syn immunogold results (<xref ref-type="fig" rid="fig6">Figure <bold>6</bold>A</xref>), PDD SAA fibrils showed the highest anti-p<italic>α</italic>Syn signal (<xref ref-type="fig" rid="fig6">Figure <bold>6</bold>D</xref>). The DLB SAA fibrils were also weakly phosphorylated, while those of PD and MSA were negative. Our results demonstrate that the brain-derived and SAA <italic>α</italic>Syn fibrils display different patterns of S129 phosphorylation.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<sec id="s3a">
<title>Strain-like properties of the brain-derived <italic>α</italic>Syn fibrils from different synucleinopathies</title>
<p>Findings in this study provide evidence of distinct ‘strain-like’ properties of the brain-derived <italic>α</italic>Syn fibrils from different synucleinopathies. First, faster seeding kinetics was observed in the brain-derived <italic>α</italic>Syn fibrils from PDD and DLB than those from PD and MSA, suggesting a distinct ‘strain’ characterized by an aggressive seeding capacity. In contrast, those from PD and MSA are discrete ‘strains’ with milder seeding capacity. Previous studies of <italic>α</italic>Syn SAA with CSF showed that PD and MSA could be distinguished using <italic>T</italic><sub>50</sub>, <italic>V</italic><sub>MAX</sub> (<bold><italic><xref ref-type="bibr" rid="c31">Poggiolini et al., 2021</xref></italic></bold>), and <italic>F</italic><sub>MAX</sub> (<bold><italic><xref ref-type="bibr" rid="c36">Shahnawaz et al., 2020</xref>, <xref ref-type="bibr" rid="c37">2017</xref></italic></bold>). However, in our <italic>α</italic>Syn SAA with brain-derived fibrils, the same parameters cannot distinguish between PD and MSA. Differences in the findings are likely to arise from the type of seeds. An unprocessed CSF would likely comprise distinct and different concentrations of <italic>α</italic>Syn species. Moreover, the choice of biosample (CSF, olfactory mucosa, skin) significantly affects the outcome of seeding kinetics (<bold><italic><xref ref-type="bibr" rid="c7">Chahine et al., 2020</xref></italic></bold>). By isolating the brain-derived <italic>α</italic>Syn fibrils, we could study the seeding kinetics of the fibrils themselves and, as a result, better understand their distinct intrinsic seeding properties.</p>
<p>Next, examining the phosphorylated brain-derived <italic>α</italic>Syn fibrils (p<italic>α</italic>Syn), we demonstrate a possible correlation between the amount of p<italic>α</italic>Syn and rapid seeding kinetics. Studies have shown that p<italic>α</italic>Syn enhances <italic>α</italic>Syn aggregation in vitro (SH-SY5Y cells) and in vivo (rodent models) (<bold><italic><xref ref-type="bibr" rid="c38">Smith et al., 2005</xref>; <xref ref-type="bibr" rid="c17">Karampetsou et al., 2017</xref></italic></bold>). However, contradicting findings have also been reported, suggesting a neuroprotective role of p<italic>α</italic>Syn (<bold><italic><xref ref-type="bibr" rid="c24">Ma et al., 2016</xref>; <xref ref-type="bibr" rid="c11">Ghanem et al., 2022</xref></italic></bold>). Although the biological role of p<italic>α</italic>Syn is unclear, we report that a higher amount of p<italic>α</italic>Syn may contribute to the more aggressive seeding kinetics observed in PDD and DLB brain-derived <italic>α</italic>Syn fibrils than those of PD and MSA.</p>
<p>Further evidence of ‘strain-like’ property was exhibited by the distinct biochemical profiles of the brain-derived <italic>α</italic>Syn fibrils from different synucleinopathies. The brain-derived <italic>α</italic>Syn fibrils from PD and MSA were more susceptible to GndHCl denaturation than PDD and DLB, indicating conformational instability of PD and MSA brain-derived <italic>α</italic>Syn fibrils. Nevertheless, it must be noted that the rapid denaturation of PD fibrils might be due to a low concentration of <italic>α</italic>Syn fibrils, as demonstrated by a lower Lewy pathology load in the entorhinal cortex. A previous study also showed that human brain-derived <italic>α</italic>Syn fibrils from DLB were more stable than MSA by using GdnHCl treatment (<bold><italic><xref ref-type="bibr" rid="c19">Lau et al., 2020</xref></italic></bold>). Interestingly, the less stable MSA fibrils propagated faster in TgM83 mice than the more stable DLB fibrils. Such inverse correlation between conformational stability and disease propagation has been characterized in prion disease (<bold><italic><xref ref-type="bibr" rid="c21">Legname et al., 2006</xref></italic></bold>). Therefore, our findings on the differential conformational stability could reflect the strain-specific characteristics of <italic>α</italic>Syn fibrils. Subsequently, it could be related to the fast disease progression of MSA compared to PDD and DLB.</p>
<p>Subsequently, by assessing the PK-resistance of the <italic>α</italic>Syn fibrils, we illustrate further the molecular diversity of <italic>α</italic>Syn fibrils. The sizes of the low MW PK-resistant fragments differed between diseases and cases within each disease. These distinct PK-resistant peptides suggest the presence of conformational variants indicative of <italic>α</italic>Syn fibrillar strains within a single disease entity. Similarly, Guo and colleagues reported evidence of distinct <italic>α</italic>Syn fibrillar conformers in different PDD patients’ brains (<bold><italic><xref ref-type="bibr" rid="c14">Guo et al., 2013</xref></italic></bold>). Our group has also shown different SAA kinetics in the CSF samples of PD patients divided into four different subtypes based on their baseline and progressive motor and non-motor symptoms (<bold><italic><xref ref-type="bibr" rid="c20">Lawton et al., 2018</xref></italic></bold>), suggesting <italic>α</italic>Syn strain heterogeneity within the same disease (<bold><italic><xref ref-type="bibr" rid="c31">Poggiolini et al., 2021</xref></italic></bold>). Finally, unlike PDD and DLB, MSA <italic>α</italic>Syn fibrils gradually disappeared upon PK treatment without being digested into small fragments. The lack of PK-resistant peptides in MSA indicates a readily digestible property of MSA <italic>α</italic>Syn fibrils. Together with its conformational instability, these biochemical properties might indicate a specific <italic>α</italic>Syn strain in MSA.</p>
<p>Interestingly, MSA fibrils also showed distinct structural features compared to those from PD, PDD, and DLB. The fibrils from MSA were predominantly ‘straight’, and those from PD, PDD, and DLB were ‘straight’ and ‘twisted’. While the ‘straight’ brain-derived fibrils were densely decorated with MJFR-14 and anti-p<italic>α</italic>Syn antibodies, confirming their identity as a phosphorylated <italic>α</italic>Syn fibril, the ‘twisted’ fibrils were not recognised by these proteins. Similarly, Spillantini and colleagues also reported a finding of ‘twisted’ fibril from the cingulate cortex of a DLB brain with no labeling by the <italic>α</italic>Syn-specific antibody (<bold><italic><xref ref-type="bibr" rid="c39">Spillantini et al., 1998</xref></italic></bold>). Further ultrastructure analysis is essential to reveal the identity of the unlabeled twisted fibrils.</p>
<p>The methodological limitations of the structural characterisation in this study should be considered. Cryo-electron microscope (EM) ultrastructure revealed the twisted structures of the MSA brain-derived <italic>α</italic>Syn fibrils and single twisted protofilament structures in PD, PDD and DLB brains (<bold><italic><xref ref-type="bibr" rid="c52">Yang et al., 2022</xref></italic></bold>). Our TEM structures may differ due to the selection of different brain regions compared to those used in the literature and the limitation of the resolving power of TEM. Future cryo-EM structural studies of <italic>α</italic>Syn fibrils from not only different synucleinopathies but also different brain regions and subtypes of PD are required to establish a more profound understanding of the molecular diversity of the <italic>α</italic>Syn conformers in synucleinopathies.</p>
</sec>
<sec id="s3b">
<title>Distinct biophysical properties between brain-derived and SAA fibrils</title>
<p>In order to assess whether the SAA fibrils truly replicate the brain-derived fibrils (the seed), we compared the biophysical characteristics of the brain-derived <italic>α</italic>Syn fibrils and their respective SAA fibrils. First, by examining the resistance to GdnHCl and PK digestion, we illustrated a prominent biochemical difference between the brain-derived and SAA fibrils. High concentrations (4-5 M) of GdnHCl completely denatured the brain-derived fibrils, whilst SAA fibrils were still resistant. This indicates that the SAA fibrils are more stable and PK-resistant than their respective brain-derived fibrils. Furthermore, the SAA fibrils from all four synucleinopathies had identical patterns of PK resistance. The SAA amplifies fibrils with uniform biochemical features, losing the intrinsic properties of the original seed fibril and failing to replicate the biochemical properties of the original brain-derived fibrils.</p>
<p>The differences in biochemical stability might arise from the distinct distribution of the fibrils. SAA fibrils were clustered in negative-stain TEM, whereas the brain-derived fibrils were distributed in single filaments (<xref ref-type="fig" rid="fig5">Figure <bold>5</bold></xref>). Also, this study used a PIPES-based buffer to amplify the SAA fibrils (<bold><italic><xref ref-type="bibr" rid="c31">Poggiolini et al., 2021</xref></italic></bold>). As the microenvironmental context of <italic>α</italic>Syn amplification substantially affects the newly amplified fibrils (<bold><italic><xref ref-type="bibr" rid="c30">Peng et al., 2018</xref>; <xref ref-type="bibr" rid="c15">Gustavsson et al., 2021</xref></italic></bold>), the artificial in vitro environment can favor the formation of specific three-dimensional structures that are more conformationally stable.</p>
<p>Next, we showed that brain-derived fibrils display a mixture of straight and twisted structures, while SAA fibrils have a unified structure: straight (PD, PDD, DLB) or twisted (MSA). The striking structural difference may be due to a dominant seeding fibril within the mixture of brain-derived fibrils. Interestingly, straight fibrils were dominant in MSA brains, but the corresponding SAA fibrils were twisted. The commonality of a particular structure in a fibrillar mixture may not be a determinant of a dominant seeding fibril. Other factors might contribute, such as metal ions (<bold><italic><xref ref-type="bibr" rid="c43">Uversky et al., 2001</xref></italic></bold>) and post-translational modifications (PTMs), which also affect seeding efficiency (<bold><italic><xref ref-type="bibr" rid="c3">Balana et al., 2023</xref></italic></bold>). Also, our PIPES-based SAA reaction buffer with 150 mM NaCl is likely to have influenced the SAA fibril structure. However, the discrete structure of the MSA SAA fibrils compared to those of PD, PDD, and DLB implies that a complex matrix of intrinsic factors within the brain-derived fraction impacts seeding amplification and the resulting fibrillar structure.</p>
<p>A recent cryo-EM analysis of the MSA brain-derived and SAA fibrils revealed striking structural differences (<bold><italic><xref ref-type="bibr" rid="c35">Schweighauser et al., 2020</xref>; <xref ref-type="bibr" rid="c23">Lövestam et al., 2021</xref></italic></bold>). A few significant differences included the protofilament fold, the inter-protofilament interface and the geometry of specific residues that shape the hydrophobic core. As the TEM has restricted resolution, future cryo-EM analyses are imperative to connect the structure to the disease heterogeneity and progression.</p>
<p>Lastly, we investigated the differences in the phosphorylation level between the brain-derived and SAA <italic>α</italic>Syn fibrils to identify differences in the PTM patterns. The brain-derived fibrils generally showed a higher phosphorylation level than the SAA fibrils. PDD and DLB SAA fibrils were weakly phosphorylated and decorated with p<italic>α</italic>Syn immunogold labels at the rare end of the fibrils (<xref ref-type="fig" rid="fig6">Figure <bold>6</bold></xref>). Combining these findings, we can argue the possibility that the SAA fibrils extended from p<italic>α</italic>Syn species dissociated from the brain-derived fibrils. Therefore, the amount of initial p<italic>α</italic>Syn fibrils in the seed might be a critical determinant of the phosphorylation state of the resulting SAA fibrils.</p>
<p>Studies have explored the pathogenicity of brain-derived <italic>α</italic>Syn fibrils in vitro using primary neurons, oligodendrocytes, and HEK cell lines expressing mutated <italic>α</italic>Syn (<bold><italic><xref ref-type="bibr" rid="c46">Woerman et al., 2018a</xref>; <xref ref-type="bibr" rid="c30">Peng et al., 2018</xref>; <xref ref-type="bibr" rid="c50">Woerman et al., 2015</xref>; <xref ref-type="bibr" rid="c51">Yamasaki et al., 2019</xref></italic></bold>). Moreover, similar pathological characterization has been done in different mouse models (<bold><italic><xref ref-type="bibr" rid="c19">Lau et al., 2020</xref>; <xref ref-type="bibr" rid="c48">Woerman et al., 2019</xref>, <xref ref-type="bibr" rid="c46">2018a</xref>; <xref ref-type="bibr" rid="c32">Prusiner et al., 2015</xref>; <xref ref-type="bibr" rid="c30">Peng et al., 2018</xref>; <xref ref-type="bibr" rid="c26">Masuda-Suzukake et al., 2013</xref>; <xref ref-type="bibr" rid="c45">Watts et al., 2013</xref>; <xref ref-type="bibr" rid="c4">Bernis et al., 2015</xref>; <xref ref-type="bibr" rid="c47">Woerman et al., 2018b</xref>, <xref ref-type="bibr" rid="c49">2020</xref></italic></bold>). Interestingly, both in vitro and in vivo, MSA brain-derived <italic>α</italic>Syn induced significant <italic>α</italic>Syn aggregation, whereas those from PD/PDD and DLB brains produced either no or low <italic>α</italic>Syn accumulation. Similar disease-specific patterns were also observed in SAA-amplified fibrils (<bold><italic><xref ref-type="bibr" rid="c36">Shahnawaz et al., 2020</xref>; <xref ref-type="bibr" rid="c44">Van der Perren et al., 2020</xref>; <xref ref-type="bibr" rid="c42">Tanudjojo et al., 2021</xref></italic></bold>). In future studies, it would be crucial to examine the brain-derived and SAA fibrils in comparison in cellular and mouse models for their pathological characteristics.</p>
<p>In summary, the distinct biochemical profiles and structures of the brain-derived <italic>α</italic>Syn fibrils from different synucleinopathies provide supporting evidence of molecular diversity of brain-derived <italic>α</italic>Syn fibrils among different synucleinopathies and individual patients. Moreover, the SAA fibrils failed to adopt the biochemical, structural and PTM properties of the seed brain-derived <italic>α</italic>Syn fibrils, which addresses a significant limitation of SAA in replicating the intrinsic biophysical properties of the seed fibrils. Therefore, our finding highlights the necessity of re-evaluating the SAA seeding mechanism and its capacity to generate disease-relevant <italic>α</italic>Syn fibrils used in different in vitro and in vivo models. Furthermore, it remains essential to investigate the human-derived <italic>α</italic>Syn fibrils in the different brain regions and in other peripheral sites to explore <italic>α</italic>Syn strains and how they may affect the progression of pathology. They also remain the most disease-specific fibrils used in cellular and animal models.</p>
</sec>
</sec>
<sec id="s4">
<title>Methods and Materials</title>
<sec id="s4a">
<title>Patient Collection</title>
<p>Brain tissues from patients with PD and PDD were obtained from the Parkinson’s UK Brain Bank (Imperial College London, UK) in accordance with approved protocols by the London Multicentre Research Ethics Committee. Brain tissues from patients with DLB, MSA and healthy controls were collected from the Oxford Brain Bank (OBB, University of Oxford, UK) in accordance with approved protocols by the South Central - Oxford C Research Ethics Committee (ref 23/SC/0241). All participants had given prior written informed consent for the brain donation. Both brain banks comply with the requirements of the Human Tissue Act 2004 and the Codes of Practice set by the Human Tissue Authority (HTA licence numbers 12275 for the Imperial and 12217 for OBB). The clinicopathological demographics of the patients and healthy controls are summarized in <xref ref-type="table" rid="tblS1">Table S1</xref>.</p>
</sec>
<sec id="s4b">
<title>Extraction of <italic>α</italic>Syn fibrils from the human brain</title>
<p>Sarkosyl insoluble <italic>α</italic>Syn fibril was extracted from the brains of PD (<italic>n</italic>=3), PDD (<italic>n</italic>=3), DLB (<italic>n</italic>=3), MSA (<italic>n</italic>=3) patients and healthy controls (<italic>n</italic>=3). The entorhinal cortex was selected for PD, PDD, and DLB, and the striatum was selected for MSA. The extraction protocol was adapted from the method presented by Schweighauser and colleagues (<bold><italic><xref ref-type="bibr" rid="c35">Schweighauser et al., 2020</xref></italic></bold>). Brain tissues (0.5 g) were homogenized in an extraction buffer of 10 mM Tris-HCl, 0.8 M NaCl, 10% sucrose and 1 mM EGTA (pH 7.5). Sarkosyl was added to a final concentration of 2% and incubated for 30 min at 37 °C. Homogenates were centrifuged at 10,000 g for 10 min at 4 °C. The supernatants were centrifuged at 100,000 g for 60 min at 4 °C. The pellet was washed, resuspended in 500 µl/g of extraction buffer, and centrifuged at 500 g for 1 min at 4 °C. The resulting supernatants were diluted 1/3 in buffer consisting of 50 mM Tris-HCl, 0.15 M NaCl, 10 % sucrose, and 0.2% sarkosyl (pH 7.5). The diluted supernatant was centrifuged at 100,000 g for 60 min at 4 °C. The resulting pellet was washed and resuspended in 250 µl/g of 30 mM Tris-HCl (pH 7.5), being the sarkosyl-insoluble fraction. The protein concentration was determined using the bicinchoninic acid assay (BCA) (Thermo Scientific). The sarkosyl insoluble fraction was aliquoted and stored at -80 °C.</p>
</sec>
<sec id="s4c">
<title><italic>α</italic>Syn seeding amplification assay (SAA)</title>
<p>The brain-derived <italic>α</italic>Syn fibrils were diluted 1:1,000 in 30 mM Tris-HCl (pH 7.5), and 2 µl was added to 98 µl of the reaction mixture consisting of 100 mM PIPES (pH 7), 150 mM NaCl, 0.1 mg/ml of recombinant <italic>α</italic>Syn (rPeptide) and 10 µM thioflavin-T (ThT) to a final reaction volume of 100 µl. Before use, the recombinant <italic>α</italic>Syn was filtered through a 100 kDa molecular weight cut-off (MWCO) filter. The reaction mixture was loaded onto a black 96-well plate with a clear bottom (Nalgene Nunc). The plate was sealed with a plate sealing film (Thermo Scientific) and incubated at 42 °C in a BMG FLUOstar Omega plate reader for 100 h with cycles of 1 min shaking (400 rpm double orbital) and 1 min rest. ThT fluorescence measurement (450 nm excitation and 480 nm emission) was taken every 30 min. Each sample was run in six replicates. The reaction end-products were ultracentrifuged at 100,000 g for 1 h at 4 °C and collected as SAA fibril.</p>
</sec>
<sec id="s4d">
<title>Conformational stability assay and immunoblotting</title>
<p>The brain-derived <italic>α</italic>Syn fibrils (10 µg) and SAA fibrils (1 µg) were treated with different GdnHCl concentrations (0-5 M) at 37 °C for 1 h on a thermoshaker (800 rpm). The reactions were stopped by reducing the GdnHCl concentration to 0.5 M. The fibrils were treated with 1 µg/ml of proteinase-K (PK) at 37 °C for 30 min on a thermoshaker (500 rpm). Digested samples were collected using ultracentrifugation at 100,000 g, 4 °C for 1 h. Tricine sample buffer (Bio-Rad) was added to the samples and boiled at 95 °C for 10 min. The samples were analyzed with 16.5% Tris-Tricine gels (Bio-Rad) and immunoblotted on nitrocellulose membranes (Amersham). Membranes were blocked with 5% skimmed milk in TBS-Tween and incubated with anti-<italic>α</italic>Syn clone 42 (BD Biosciences, 1:1,000 dilution). In a slot blot, 2 µg of protein was immobilized on a nitrocellulose membrane (Amersham) by filtration using a slot blot apparatus (GE Healthcare). The membrane was blocked with 5% skimmed milk and probed with MJFR-14-6-4-2 (Abcam, 1:3000 dilution) and EP1536Y (Abcam, 1:1,000 dilution). The membranes were developed using an ECL Western blot detection kit (Amersham). Semi-quantitative analysis of the slot blot data was performed using ImageJ.</p>
</sec>
<sec id="s4e">
<title>Transmission electron microscopy (TEM) and immunolabeling electron microscopy</title>
<p>Five µl of 0.5 µg brain-derived <italic>α</italic>Syn fibrils and 5 µl of SAA fibrils were applied to glow-discharged carbon grids (Agar Scientific, 300 mesh) and incubated for 2 min. The grid was washed with water for 10 sec and negatively stained with 2% uranyl acetate for 10 sec. Stained samples were imaged on an FEI Tecnai T12 microscope operated at 120 kV.</p>
<p>For immunolabeling, the fibrils were applied to glow-discharged carbon grids and blocked with a blocking buffer (0.2% fish gelatin in PBS). Then, the grid was incubated with antibodies targeting the phosphorylated <italic>α</italic>Syn (EP1536Y, Abcam, 1:20 dilution) and <italic>α</italic>Syn fibril conformer (MJFR-14-6-4-2, Abcam, 1:50 dilution). After washing with blocking buffer, the sample was incubated with goat anti-rabbit IgG coupled with 10 nm gold (Ab27234, Abcam) diluted 1:10 in the blocking buffer. Then, the grid was fixed with 0.1% glutaraldehyde in PBS. The samples were stained with 2% uranyl acetate for 30 s.</p>
</sec>
<sec id="s4f">
<title>Immunohistochemistry</title>
<p>Six μm-thick sections of formalin-fixed paraffin-embedded (FFPE) human brain tissue sections were de-paraffinized in xylene (3 x 5 min) and rehydrated through decreasing concentration of industrial denatured alcohol (IDA) (100%, 100%, 90%, 70%; 5 min each) and subsequently in distilled water (5 min). For antigen retrieval, sections were treated with 70% formic acid for 15 min. The sections were then blocked with 3% H<sub>2</sub>O<sub>2</sub> for 20 min and with 10% fetal bovine serum (FBS) in PBS for 30 min. Sections were incubated with anti-<italic>α</italic>Syn clone 42 (BD Biosciences) diluted 1:1,000 in 10% FBS overnight at 4 °C. After washing with PBS (3 x 5 min), sections were incubated with Ms/Rb-HRP secondary antibody (Agilent Technologies) for 30 min at RT. Sections were developed with Dako DAB (Agilent Technologies) and counterstained with haematoxylin. Finally, sections were mounted to coverslips with DPX (Thermo Scientific).</p>
</sec>
<sec id="s4g">
<title>Statistical analysis</title>
<p>Mann-Whitney U test was used when comparing two independent groups. Independent Kruskal-Wallis Test was performed to compare more than three groups for SAA kinetic parameters <xref ref-type="fig" rid="fig2">Figure <bold>2</bold></xref>, fibril dimensions (PD, PDD, DLB, and MSA) <xref ref-type="fig" rid="fig5">Figure <bold>5</bold></xref>, and the amount of phosphorylated <italic>α</italic>Syn fibrils <xref ref-type="fig" rid="fig6">Figure <bold>6</bold></xref>. <italic>P</italic> values &lt; 0.05 were considered statistically significant. All statistical analyses were performed using SPSS Statistics, Version 28.</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank all the patients and their families for the valuable brain donations for research. We also want to thank Dr. Errin Johnson and the Oxford bioimaging facility for providing access and training for transmission electron microscopy and assisting with acquiring the imaging data. We acknowledge Dr. Alan King Lun Liu for helping us with the case selection and analysis of the clinical summary of the patients. We acknowledge the Oxford Brain Bank, supported by Brains for Dementia Research (BDR) (Alzheimer Society and Alzheimer Research UK) and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). LP is supported by the GSK-Institute of Molecular &amp; Computational Medicine, NIHR Oxford BRC, Parkinson Foundation, the Michael J. Fox Foundation, the Galen and Hilary Weston Foundation, and the National Institute of Health. LC is supported by NIHR Oxford BRC.</p>
</ack>
<sec id="s5">
<title>Supplementary Material</title>
<table-wrap id="tblS1" orientation="portrait" position="float">
<label>Table S1.</label>
<caption><title>Clinicopathological summary of the patients included in this study.</title>
<p>The table summarizes the clinical and pathological reports of the patients included in this study. PD, Parkinson’s disease; PDD, Parkinson’s disease with dementia; DLB, dementia with Lewy body; MSA, multiple system atrophy; CTR, control; ECtx, entorhinal cortex; BG, basal ganglia; M, male; F, female; AD, Alzheimer’s disease; CVD, cardiovascular disease; <italic>α</italic>Syn, <italic>α</italic>-synuclein.</p></caption>
<graphic xlink:href="560803v1_tblS1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<fig id="figS1" position="float" fig-type="figure">
<label>Figure S1.</label>
<caption><title>Raw data of the <italic>α</italic>Syn SAA reaction seeded with <italic>α</italic>Syn fibrils from PD, PDD, DLB, MSA, and healthy control brains.</title>
<p>The curves represent the average of 6 replicates, and error bars indicate ± one standard deviation (SD). RFU, relative fluorescence unit.</p></caption>
<graphic xlink:href="560803v1_figS1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS2" position="float" fig-type="figure">
<label>Figure S2.</label>
<caption><title>The full biochemical profiles of the brain-derived and SAA <italic>α</italic>Syn fibrils from all the cases.</title>
<p>The brain-derived (BD) and SAA <italic>α</italic>Syn fibrils from all 3 cases of (<bold>A</bold>) PD, (<bold>B</bold>) PDD, (<bold>C</bold>) DLB, and (<bold>D</bold>) MSA were treated with GdnHCl (0-5 M) and PK (1 µ g/ml). The antibody clone 42 (BD Biosciences) was used to reveal the PK-resistant peptides. Black arrows mark the five PK-resistant peptides revealed in the SAA fibrils. The molecular weights of the protein standards are shown in kilodaltons (kDa). SAA, seeding amplification assay; GndHCl, guanidine-hydrochloride; PK, proteinase-K.</p></caption>
<graphic xlink:href="560803v1_figS2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS3" position="float" fig-type="figure">
<label>Figure S3.</label>
<caption><title>Immunohistochemical detection of <italic>α</italic>Syn in PD, PDD, DLB, and MSA brains.</title>
<p>The entorhinal cortex (PD, PDD, DLB) and striatum (MSA) were stained with total <italic>α</italic>Syn using antibody clone 42 (BD Biosciences). (<bold>A-C</bold>) PD cases 1-3. (<bold>D-F</bold>) PDD cases 1-3. (<bold>G-I</bold>) DLB cases 1-3. (<bold>J-L</bold>) MSA cases 1-3. Scale bars = 20 µm and 200 µm.</p></caption>
<graphic xlink:href="560803v1_figS3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS4" position="float" fig-type="figure">
<label>Figure S4.</label>
<caption><title>pS129 immunogold TEM images of the brain-derived <italic>α</italic>Syn fibrils.</title>
<p>The brain-derived <italic>α</italic>Syn fibrils were labeled with anti-p<italic>α</italic>Syn (pS129) and imaged at low magnification to compare the relative quantities of the p<italic>α</italic>Syn fibrils between the diseases. All three cases were imaged for each disease (<bold>A</bold>) PD, (<bold>B</bold>) PDD, (<bold>C</bold>) DLB, and (<bold>D</bold>) MSA. The amount of p<italic>α</italic>Syn fibrils was examined using slot blots. Red arrows indicate labeled fibrils. Scale bar = 200 µm.</p></caption>
<graphic xlink:href="560803v1_figS4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS5" position="float" fig-type="figure">
<label>Figure S5.</label>
<caption><title>TEM images of the twisted brain-derived <italic>α</italic>Syn fibrils.</title>
<p>PD, PDD, and MSA brain-derived fibrils displayed intertwined fibrils with left-handed helix and DLB brain-derived fibrils with right-handed helix. Helical twists are highlighted in pink and white. Scale bar = 50 µm.</p></caption>
<graphic xlink:href="560803v1_figS5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS6" position="float" fig-type="figure">
<label>Figure S6.</label>
<caption><title>Comparison of the length and width of the brain-derived and SAA <italic>α</italic>Syn fibrils.</title>
<p>Comparison of the (<bold>A</bold>) lengths and the (<bold>B</bold>) widths of the brain-derived and SAA <italic>α</italic>Syn fibrils. Thirty fibrils were counted for each case. Thus, a total of 90 data points were plotted (<italic>N</italic> = 90). The black bold line indicates an average. BD, brain-derived; SAA, seeding amplification assay. **** <italic>P</italic> ≤ 0.001.</p></caption>
<graphic xlink:href="560803v1_figS6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Altay</surname>, <given-names>M. F.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>A. K. L.</given-names></string-name>, <string-name><surname>Holton</surname>, <given-names>J. L.</given-names></string-name>, <string-name><surname>Parkkinen</surname>, <given-names>L.</given-names></string-name>, and <string-name><surname>Lashuel</surname>, <given-names>H. A.</given-names></string-name> (<year>2022</year>). <article-title>Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across lewy body disor-ders</article-title>. <source>Acta Neuropathologica Communications</source>, <volume>10</volume>(<issue>1</issue>):<fpage>163</fpage>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Ayers</surname>, <given-names>J. I.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Monteiro</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Woerman</surname>, <given-names>A. L.</given-names></string-name>, <string-name><surname>Lazar</surname>, <given-names>A. A.</given-names></string-name>, <string-name><surname>Condello</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Paras</surname>, <given-names>N. A.</given-names></string-name>, and <string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name> (<year>2022</year>). <article-title>Different <italic>α</italic>-synuclein prion strains cause dementia with lewy bodies and multiple system atrophy</article-title>. <source>Proc Natl Acad Sci U S A</source>, <volume>119</volume>(<issue>6</issue>).</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="other"><string-name><surname>Balana</surname>, <given-names>A. T.</given-names></string-name>, <string-name><surname>Mahul-Mellier</surname>, <given-names>A.-L.</given-names></string-name>, <string-name><surname>Nguyen</surname>, <given-names>B. A.</given-names></string-name>, <string-name><surname>Horvath</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Javed</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hard</surname>, <given-names>E. R.</given-names></string-name>, <string-name><surname>Jasiqi</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Singh</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Afrin</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Pedretti</surname>, <given-names>R.</given-names></string-name>, <etal>et al.</etal> (<year>2023</year>). <article-title>O-glcnac modification forces the formation of an <italic>α</italic>-synuclein amyloid-strain with notably diminished seeding activity and pathology</article-title>. <source>bioRxiv</source>, pages 2023–03.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><string-name><surname>Bernis</surname>, <given-names>M. E.</given-names></string-name>, <string-name><surname>Babila</surname>, <given-names>J. T.</given-names></string-name>, <string-name><surname>Breid</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Wusten</surname>, <given-names>K. A.</given-names></string-name>, <string-name><surname>Wullner</surname>, <given-names>U.</given-names></string-name>, and <string-name><surname>Tamguney</surname>, <given-names>G.</given-names></string-name> (<year>2015</year>). <article-title>Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein</article-title>. <source>Acta Neuropathol Commun</source>, <volume>3</volume>:<fpage>75</fpage>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><string-name><surname>Bousset</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Pieri</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ruiz-Arlandis</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Gath</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Jensen</surname>, <given-names>P. H.</given-names></string-name>, <string-name><surname>Habenstein</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Madiona</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Olieric</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Bockmann</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Meier</surname>, <given-names>B. H.</given-names></string-name>, and <string-name><surname>Melki</surname>, <given-names>R.</given-names></string-name> (<year>2013</year>). <article-title>Structural and functional characterization of two alpha-synuclein strains</article-title>. <source>Nat Commun</source>, <volume>4</volume>:<fpage>2575</fpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Braak</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Del Tredici</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Rub</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>de Vos</surname>, <given-names>R. A.</given-names></string-name>, <string-name><surname>Jansen Steur</surname>, <given-names>E. N.</given-names></string-name>, and <string-name><surname>Braak</surname>, <given-names>E.</given-names></string-name> (<year>2003</year>). <article-title>Staging of brain pathology related to sporadic parkinson’s disease</article-title>. <source>Neurobiol Aging</source>, <volume>24</volume>(<issue>2</issue>):<fpage>197</fpage>–<lpage>211</lpage>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><string-name><surname>Chahine</surname>, <given-names>L. M.</given-names></string-name>, <string-name><surname>Beach</surname>, <given-names>T. G.</given-names></string-name>, <string-name><surname>Brumm</surname>, <given-names>M. C.</given-names></string-name>, <string-name><surname>Adler</surname>, <given-names>C. H.</given-names></string-name>, <string-name><surname>Coffey</surname>, <given-names>C. S.</given-names></string-name>, <string-name><surname>Mosovsky</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Caspell-Garcia</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Serrano</surname>, <given-names>G. E.</given-names></string-name>, <string-name><surname>Munoz</surname>, <given-names>D. G. III C. L. W.</given-names></string-name>, <string-name><surname>Crary</surname>, <given-names>J. F.</given-names></string-name>, <string-name><surname>Jennings</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Taylor</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Foroud</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Arnedo</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Kopil</surname>, <given-names>C. M.</given-names></string-name>, <string-name><surname>Riley</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Dave</surname>, <given-names>K. D.</given-names></string-name>, <string-name><surname>Mollenhauer</surname>, <given-names>B.</given-names></string-name>, and <collab>for the Systemic Synuclein Sampling Study</collab> (<year>2020</year>). <article-title>In vivo distribution of <italic>α</italic>-synuclein in multiple tissues and biofluids in parkinson disease</article-title>. <source>Neurology</source>, <volume>95</volume>(<issue>9</issue>):<fpage>e1267</fpage>–<lpage>e1284</lpage>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><string-name><surname>Fairfoul</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>McGuire</surname>, <given-names>L. I.</given-names></string-name>, <string-name><surname>Pal</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ironside</surname>, <given-names>J. W.</given-names></string-name>, <string-name><surname>Neumann</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Christie</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Joachim</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Esiri</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Evetts</surname>, <given-names>S. G.</given-names></string-name>, <string-name><surname>Rolinski</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Baig</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Ruffmann</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wade-Martins</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>M. T.</given-names></string-name>, <string-name><surname>Parkkinen</surname>, <given-names>L.</given-names></string-name>, and <string-name><surname>Green</surname>, <given-names>A. J.</given-names></string-name> (<year>2016</year>). <article-title>Alphasynuclein rt-quic in the csf of patients with alpha-synucleinopathies</article-title>. <source>Ann Clin Transl Neurol</source>, <volume>3</volume>(<issue>10</issue>):<fpage>812</fpage>–<lpage>818</lpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><string-name><surname>Forno</surname>, <given-names>L. S.</given-names></string-name> (<year>1988</year>). <article-title>The neuropathology of parkinson’s disease</article-title>. <source>Progress in Parkinson Research</source>, pages 11–21.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Frieg</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Geraets</surname>, <given-names>J. A.</given-names></string-name>, <string-name><surname>Strohäker</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Dienemann</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Mavroeidi</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Jung</surname>, <given-names>B. C.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>W. S.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>S.-J.</given-names></string-name>, <string-name><surname>Xilouri</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zweckstetter</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Schröder</surname>, <given-names>G. F.</given-names></string-name> (<year>2022</year>). <article-title>Quaternary structure of patient-homogenate amplified <italic>α</italic>-synuclein fibrils modulates seeding of endogenous <italic>α</italic>-synuclein</article-title>. <source>Communications Biology</source>, <volume>5</volume>(<issue>1</issue>):<fpage>1040</fpage>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><string-name><surname>Ghanem</surname>, <given-names>S. S.</given-names></string-name>, <string-name><surname>Majbour</surname>, <given-names>N. K.</given-names></string-name>, <string-name><surname>Vaikath</surname>, <given-names>N. N.</given-names></string-name>, <string-name><surname>Ardah</surname>, <given-names>M. T.</given-names></string-name>, <string-name><surname>Erskine</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Jensen</surname>, <given-names>N. M.</given-names></string-name>, <string-name><surname>Fayyad</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sudhakaran</surname>, <given-names>I. P.</given-names></string-name>, <string-name><surname>Vasili</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Melachroinou</surname>, <given-names>K.</given-names></string-name>, <etal>et al.</etal> (<year>2022</year>). <article-title><italic>α</italic>-synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity</article-title>. <source>Proceedings of the National Academy of Sciences</source>, <volume>119</volume>(<issue>15</issue>):<fpage>e2109617119</fpage>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><string-name><surname>Groveman</surname>, <given-names>B. R.</given-names></string-name>, <string-name><surname>Orru</surname>, <given-names>C. D.</given-names></string-name>, <string-name><surname>Hughson</surname>, <given-names>A. G.</given-names></string-name>, <string-name><surname>Raymond</surname>, <given-names>L. D.</given-names></string-name>, <string-name><surname>Zanusso</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Ghetti</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Campbell</surname>, <given-names>K. J.</given-names></string-name>, <string-name><surname>Safar</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Galasko</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Caughey</surname>, <given-names>B.</given-names></string-name> (<year>2018</year>). <article-title>Rapid and ultra-sensitive quantitation of disease-associated alphasynuclein seeds in brain and cerebrospinal fluid by alphasyn rt-quic</article-title>. <source>Acta Neuropathol Commun</source>, <volume>6</volume>(<issue>1</issue>):<fpage>7</fpage>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>Guerrero-Ferreira</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Taylor</surname>, <given-names>N. M.</given-names></string-name>, <string-name><surname>Arteni</surname>, <given-names>A. A.</given-names></string-name>, <string-name><surname>Kumari</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Mona</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Ringler</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Britschgi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lauer</surname>, <given-names>M. E.</given-names></string-name>, <string-name><surname>Makky</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Verasdonck</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Riek</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Melki</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Meier</surname>, <given-names>B. H.</given-names></string-name>, <string-name><surname>Bockmann</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bousset</surname>, <given-names>L.</given-names></string-name>, and <string-name><surname>Stahlberg</surname>, <given-names>H.</given-names></string-name> (<year>2019</year>). <article-title>Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy</article-title>. <source>Elife</source>, <volume>8</volume>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Guo</surname>, <given-names>J. L.</given-names></string-name>, <string-name><surname>Covell</surname>, <given-names>D. J.</given-names></string-name>, <string-name><surname>Daniels</surname>, <given-names>J. P.</given-names></string-name>, <string-name><surname>Iba</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Stieber</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Riddle</surname>, <given-names>D. M.</given-names></string-name>, <string-name><surname>Kwong</surname>, <given-names>L. K.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Trojanowski</surname>, <given-names>J. Q.</given-names></string-name>, and <string-name><surname>Lee</surname>, <given-names>V. M.</given-names></string-name> (<year>2013</year>). <article-title>Distinct <italic>α</italic>-synuclein strains differentially promote tau inclusions in neurons</article-title>. <source>Cell</source>, <volume>154</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>17</lpage>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><string-name><surname>Gustavsson</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Savchenko</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Klementieva</surname>, <given-names>O.</given-names></string-name>, and <string-name><surname>Roybon</surname>, <given-names>L.</given-names></string-name> (<year>2021</year>). <article-title>The intracellular milieu of Parkinson’s disease patient brain cells modulates alpha-synuclein protein aggregation</article-title>. <source>Acta Neuropathologica Communications</source>, <volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><string-name><surname>Holec</surname>, <given-names>S. A. M.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Oehler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ooi</surname>, <given-names>F. K.</given-names></string-name>, <string-name><surname>Mordes</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Olson</surname>, <given-names>S. H.</given-names></string-name>, <string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name>, and <string-name><surname>Woerman</surname>, <given-names>A. L.</given-names></string-name> (<year>2022</year>). <article-title>Multiple system atrophy prions transmit neurological disease to mice expressing wild-type human <italic>α</italic>-synuclein</article-title>. <source>Acta Neuropathol</source>, <volume>144</volume>(<issue>4</issue>):<fpage>677</fpage>–<lpage>690</lpage>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Karampetsou</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ardah</surname>, <given-names>M. T.</given-names></string-name>, <string-name><surname>Semitekolou</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Polissidis</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Samiotaki</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kalomoiri</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Majbour</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Xanthou</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>El-Agnaf</surname>, <given-names>O. M. A.</given-names></string-name>, and <string-name><surname>Vekrellis</surname>, <given-names>K.</given-names></string-name> (<year>2017</year>). <article-title>Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice</article-title>. <source>Scientific Reports</source>, <volume>7</volume>(<issue>1</issue>):<fpage>16533</fpage>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Kuzkina</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bargar</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Schmitt</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Rößle</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Schubert</surname>, <given-names>A.-L.</given-names></string-name>, <string-name><surname>Tatsuoka</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Gunzler</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Zou</surname>, <given-names>W.-Q.</given-names></string-name>, <string-name><surname>Volkmann</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sommer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Doppler</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Chen</surname>, <given-names>S. G.</given-names></string-name> (<year>2021</year>). <article-title>Diagnostic value of skin rt-quic in parkinson’s disease: a two-laboratory study</article-title>. <source>npj Parkinson’s Disease</source>, <volume>7</volume>(<issue>1</issue>):<fpage>99</fpage>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><string-name><surname>Lau</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>So</surname>, <given-names>R. W. L.</given-names></string-name>, <string-name><surname>Lau</surname>, <given-names>H. H. C.</given-names></string-name>, <string-name><surname>Sang</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Ruiz-Riquelme</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Fleck</surname>, <given-names>S. C.</given-names></string-name>, <string-name><surname>Stuart</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Menon</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Visanji</surname>, <given-names>N. P.</given-names></string-name>, <string-name><surname>Meisl</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Faidi</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Marano</surname>, <given-names>M. M.</given-names></string-name>, <string-name><surname>Schmitt-Ulms</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Fraser</surname>, <given-names>P. E.</given-names></string-name>, <string-name><surname>Tandon</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hyman</surname>, <given-names>B. T.</given-names></string-name>, <string-name><surname>Wille</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ingelsson</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Klenerman</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Watts</surname>, <given-names>J. C.</given-names></string-name> (<year>2020</year>). <article-title>alpha-synuclein strains target distinct brain regions and cell types</article-title>. <source>Nat Neurosci</source>, <volume>23</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>31</lpage>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>Lawton</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ben-Shlomo</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>May</surname>, <given-names>M. T.</given-names></string-name>, <string-name><surname>Baig</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Barber</surname>, <given-names>T. R.</given-names></string-name>, <string-name><surname>Klein</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Swallow</surname>, <given-names>D. M.</given-names></string-name>, <string-name><surname>Malek</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Grosset</surname>, <given-names>K. A.</given-names></string-name>, and <string-name><surname>Bajaj</surname>, <given-names>N.</given-names></string-name> (<year>2018</year>). <article-title>Developing and validating parkinson’s disease subtypes and their motor and cognitive progression</article-title>. <source>Journal of Neurology, Neurosurgery &amp; Psychiatry</source>, <volume>89</volume>(<issue>12</issue>):<fpage>1279</fpage>–<lpage>1287</lpage>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Legname</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Nguyen</surname>, <given-names>H.-O. B.</given-names></string-name>, <string-name><surname>Peretz</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Cohen</surname>, <given-names>F. E.</given-names></string-name>, <string-name><surname>DeArmond</surname>, <given-names>S. J.</given-names></string-name>, and <string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name> (<year>2006</year>). <article-title>Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes</article-title>. <source>Proceedings of the National Academy of Sciences</source>, <volume>103</volume>(<issue>50</issue>):<fpage>19105</fpage>–<lpage>19110</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Li</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Ge</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Murray</surname>, <given-names>K. A.</given-names></string-name>, <string-name><surname>Sheth</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Nair</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Sawaya</surname>, <given-names>M. R.</given-names></string-name>, <string-name><surname>Shin</surname>, <given-names>W. S.</given-names></string-name>, <string-name><surname>Boyer</surname>, <given-names>D. R.</given-names></string-name>, <string-name><surname>Ye</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Eisenberg</surname>, <given-names>D. S.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>Z. H.</given-names></string-name>, and <string-name><surname>Jiang</surname>, <given-names>L.</given-names></string-name> (<year>2018</year>). <article-title>Cryo-em of full-length <italic>α</italic>-synuclein reveals fibril polymorphs with a common structural kernel</article-title>. <source>Nat Commun</source>, <volume>9</volume>(<issue>1</issue>):<fpage>3609</fpage>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Lövestam</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Schweighauser</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Matsubara</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Murayama</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Tomita</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Ando</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Hasegawa</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Yoshida</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tarutani</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Hasegawa</surname>, <given-names>M.</given-names></string-name> (<year>2021</year>). <article-title>Seeded assembly in vitro does not replicate the structures of <italic>α</italic>-synuclein filaments from multiple system atrophy</article-title>. <source>FEBS Open bio</source>, <volume>11</volume>(<issue>4</issue>):<fpage>999</fpage>–<lpage>1013</lpage>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Ma</surname>, <given-names>M.-R.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>Z.-W.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>Y.-F.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>Y.-X.</given-names></string-name>, and <string-name><surname>Li</surname>, <given-names>Y.-M.</given-names></string-name> (<year>2016</year>). <article-title>Phosphorylation induces distinct alphasynuclein strain formation</article-title>. <source>Scientific Reports</source>, <volume>6</volume>(<issue>1</issue>):<fpage>37130</fpage>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Mammana</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Baiardi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Rossi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Franceschini</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Donadio</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Capellari</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Caughey</surname>, <given-names>B.</given-names></string-name>, and <string-name><surname>Parchi</surname>, <given-names>P.</given-names></string-name> (<year>2020</year>). <article-title>Detection of prions in skin punch biopsies of creutzfeldt-jakob disease patients</article-title>. <source>Ann Clin Transl Neurol</source>, <volume>7</volume>(<issue>4</issue>):<fpage>559</fpage>–<lpage>564</lpage>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="other"><string-name><surname>Masuda-Suzukake</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Nonaka</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Hosokawa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Oikawa</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Arai</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Akiyama</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Mann</surname>, <given-names>D. M.</given-names></string-name>, and <string-name><surname>Hasegawa</surname>, <given-names>M.</given-names></string-name> (<year>2013</year>). <article-title>Prion-like spreading of pathological <italic>α</italic>-synuclein in brain</article-title>. <source>Brain, 136(Pt 4):1128–38</source>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="other"><string-name><surname>Melki</surname>, <given-names>R.</given-names></string-name> (<year>2017</year>). <source>How the shapes of seeds can influence pathology</source>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>Papp</surname>, <given-names>M. I.</given-names></string-name>, <string-name><surname>Kahn</surname>, <given-names>J. E.</given-names></string-name>, and <string-name><surname>Lantos</surname>, <given-names>P. L.</given-names></string-name> (<year>1989</year>). <article-title>Glial cytoplasmic inclusions in the cns of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and shy-drager syndrome)</article-title>. <source>J Neurol Sci</source>, <volume>94</volume>(<issue>1-3</issue>):<fpage>79</fpage>–<lpage>100</lpage>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Peelaerts</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Bousset</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Van der Perren</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Moskalyuk</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Pulizzi</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Giugliano</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Van den Haute</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Melki</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Baekelandt</surname>, <given-names>V.</given-names></string-name> (<year>2015</year>). <article-title>alpha-synuclein strains cause distinct synucleinopathies after local and systemic administration</article-title>. <source>Nature</source>, <volume>522</volume>(<issue>7556</issue>):<fpage>340</fpage>–<lpage>4</lpage>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><string-name><surname>Peng</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Gathagan</surname>, <given-names>R. J.</given-names></string-name>, <string-name><surname>Covell</surname>, <given-names>D. J.</given-names></string-name>, <string-name><surname>Medellin</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Stieber</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Robinson</surname>, <given-names>J. L.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Pitkin</surname>, <given-names>R. M.</given-names></string-name>, <string-name><surname>Olufemi</surname>, <given-names>M. F.</given-names></string-name>, <string-name><surname>Luk</surname>, <given-names>K. C.</given-names></string-name>, <string-name><surname>Trojanowski</surname>, <given-names>J. Q.</given-names></string-name>, and <string-name><surname>Lee</surname>, <given-names>V. M.</given-names></string-name> (<year>2018</year>). <article-title>Cellular milieu imparts distinct pathological alphasynuclein strains in alpha-synucleinopathies</article-title>. <source>Nature</source>, <volume>557</volume>(<issue>7706</issue>):<fpage>558</fpage>–<lpage>563</lpage>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="other"><string-name><surname>Poggiolini</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Gupta</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Lawton</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>El-Turabi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Querejeta-Coma</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Trenkwalder</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Sixel-Döring</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Foubert-Samier</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Le Traon</surname>, <given-names>A. P.</given-names></string-name>, <string-name><surname>Plazzi</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Biscarini</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Montplaisir</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gagnon</surname>, <given-names>J. F.</given-names></string-name>, <string-name><surname>Postuma</surname>, <given-names>R. B.</given-names></string-name>, <string-name><surname>Antelmi</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Meissner</surname>, <given-names>W. G.</given-names></string-name>, <string-name><surname>Mollenhauer</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Ben-Shlomo</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>M. T.</given-names></string-name>, and <string-name><surname>Parkkinen</surname>, <given-names>L.</given-names></string-name> (<year>2021</year>). <article-title>Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies</article-title>. <source>Brain</source>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name>, <string-name><surname>Woerman</surname>, <given-names>A. L.</given-names></string-name>, <string-name><surname>Mordes</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Watts</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Rampersaud</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Berry</surname>, <given-names>D. B.</given-names></string-name>, <string-name><surname>Patel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Oehler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lowe</surname>, <given-names>J. K.</given-names></string-name>, <string-name><surname>Kravitz</surname>, <given-names>S. N.</given-names></string-name>, <string-name><surname>Geschwind</surname>, <given-names>D. H.</given-names></string-name>, <string-name><surname>Glidden</surname>, <given-names>D. V.</given-names></string-name>, <string-name><surname>Halliday</surname>, <given-names>G. M.</given-names></string-name>, <string-name><surname>Middleton</surname>, <given-names>L. T.</given-names></string-name>, <string-name><surname>Gentleman</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Grinberg</surname>, <given-names>L. T.</given-names></string-name>, and <string-name><surname>Giles</surname>, <given-names>K.</given-names></string-name> (<year>2015</year>). <article-title>Evidence for <italic>α</italic>-synuclein prions causing multiple system atrophy in humans with parkinsonism</article-title>. <source>Proc Natl Acad Sci U S A</source>, <volume>112</volume>(<issue>38</issue>):<fpage>E5308</fpage>–<lpage>17</lpage>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><string-name><surname>Sano</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Atarashi</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Ishibashi</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Nakagaki</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Satoh</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Nishida</surname>, <given-names>N.</given-names></string-name> (<year>2014</year>). <article-title>Conformational properties of prion strains can be transmitted to recombinant prion protein fibrils in real-time quaking-induced conversion</article-title>. <source>J Virol</source>, <volume>88</volume>(<issue>20</issue>):<fpage>11791</fpage>–<lpage>801</lpage>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Sano</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Atarashi</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Satoh</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ishibashi</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Nakagaki</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Iwasaki</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yoshida</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Murayama</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Mishima</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Nishida</surname>, <given-names>N.</given-names></string-name> (<year>2018</year>). <article-title>Prion-like seeding of misfolded <italic>α</italic>-synuclein in the brains of dementia with lewy body patients in rt-quic</article-title>. <source>Mol Neurobiol</source>, <volume>55</volume>(<issue>5</issue>):<fpage>3916</fpage>–<lpage>3930</lpage>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="other"><string-name><surname>Schweighauser</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Tarutani</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kametani</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Murzin</surname>, <given-names>A. G.</given-names></string-name>, <string-name><surname>Ghetti</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Matsubara</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Tomita</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Ando</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Hasegawa</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Murayama</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yoshida</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Hasegawa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Scheres</surname>, <given-names>S. H. W.</given-names></string-name>, and <string-name><surname>Goedert</surname>, <given-names>M.</given-names></string-name> (<year>2020</year>). <article-title>Structures of <italic>α</italic>-synuclein filaments from multiple system atrophy</article-title>. <source>Nature</source>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><string-name><surname>Shahnawaz</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mukherjee</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Pritzkow</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Mendez</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Rabadia</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Schmeichel</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Singer</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Tsai</surname>, <given-names>A. L.</given-names></string-name>, <string-name><surname>Shirani</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Nilsson</surname>, <given-names>K. P. R.</given-names></string-name>, <string-name><surname>Low</surname>, <given-names>P. A.</given-names></string-name>, and <string-name><surname>Soto</surname>, <given-names>C.</given-names></string-name> (<year>2020</year>). <article-title>Discriminating alpha-synuclein strains in parkinson’s disease and multiple system atrophy</article-title>. <source>Nature</source>, <volume>578</volume>(<issue>7794</issue>):<fpage>273</fpage>–<lpage>277</lpage>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><string-name><surname>Shahnawaz</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tokuda</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Waragai</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mendez</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Ishii</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Trenkwalder</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Mollenhauer</surname>, <given-names>B.</given-names></string-name>, and <string-name><surname>Soto</surname>, <given-names>C.</given-names></string-name> (<year>2017</year>). <article-title>Development of a biochemical diagnosis of parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid</article-title>. <source>JAMA Neurol</source>, <volume>74</volume>(<issue>2</issue>):<fpage>163</fpage>–<lpage>172</lpage>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><string-name><surname>Smith</surname>, <given-names>W. W.</given-names></string-name>, <string-name><surname>Margolis</surname>, <given-names>R. L.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Troncoso</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>M. K.</given-names></string-name>, <string-name><surname>Dawson</surname>, <given-names>V. L.</given-names></string-name>, <string-name><surname>Dawson</surname>, <given-names>T. M.</given-names></string-name>, <string-name><surname>Iwatsubo</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Ross</surname>, <given-names>C. A.</given-names></string-name> (<year>2005</year>). <article-title><italic>α</italic>-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in sh-sy5y cells</article-title>. <source>Journal of Neuroscience</source>, <volume>25</volume>(<issue>23</issue>):<fpage>5544</fpage>–<lpage>5552</lpage>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><string-name><surname>Spillantini</surname>, <given-names>M. G.</given-names></string-name>, <string-name><surname>Crowther</surname>, <given-names>R. A.</given-names></string-name>, <string-name><surname>Jakes</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Hasegawa</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Goedert</surname>, <given-names>M.</given-names></string-name> (<year>1998</year>). <article-title>alpha-synuclein in filamentous inclusions of lewy bodies from parkinson’s disease and dementia with lewy bodies</article-title>. <source>Proc Natl Acad Sci U S A</source>, <volume>95</volume>(<issue>11</issue>):<fpage>6469</fpage>–<lpage>73</lpage>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><string-name><surname>Spillantini</surname>, <given-names>M. G.</given-names></string-name>, <string-name><surname>Schmidt</surname>, <given-names>M. L.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>V. M.</given-names></string-name>, <string-name><surname>Trojanowski</surname>, <given-names>J. Q.</given-names></string-name>, <string-name><surname>Jakes</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Goedert</surname>, <given-names>M.</given-names></string-name> (<year>1997</year>). <article-title>Alpha-synuclein in lewy bodies</article-title>. <source>Nature</source>, <volume>388</volume>(<issue>6645</issue>):<fpage>839</fpage>–<lpage>40</lpage>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><string-name><surname>Strohaker</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Jung</surname>, <given-names>B. C.</given-names></string-name>, <string-name><surname>Liou</surname>, <given-names>S. H.</given-names></string-name>, <string-name><surname>Fernandez</surname>, <given-names>C. O.</given-names></string-name>, <string-name><surname>Riedel</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Becker</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Halliday</surname>, <given-names>G. M.</given-names></string-name>, <string-name><surname>Bennati</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>W. S.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>S. J.</given-names></string-name>, and <string-name><surname>Zweckstetter</surname>, <given-names>M.</given-names></string-name> (<year>2019</year>). <article-title>Structural heterogeneity of alpha-synuclein fibrils amplified from patient brain extracts</article-title>. <source>Nat Commun</source>, <volume>10</volume>(<issue>1</issue>):<fpage>5535</fpage>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><string-name><surname>Tanudjojo</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Shaikh</surname>, <given-names>S. S.</given-names></string-name>, <string-name><surname>Fenyi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bousset</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Agarwal</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Marsh</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zois</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Heman-Ackah</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Fischer</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Sims</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Melki</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Tofaris</surname>, <given-names>G. K.</given-names></string-name> (<year>2021</year>). <article-title>Phenotypic manifestation of <italic>α</italic>-synuclein strains derived from parkinson’s disease and multiple system atrophy in human dopaminergic neurons</article-title>. <source>Nature Communications</source>, <volume>12</volume>(<issue>1</issue>):<fpage>3817</fpage>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><string-name><surname>Uversky</surname>, <given-names>V. N.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Fink</surname>, <given-names>A. L.</given-names></string-name> (<year>2001</year>). <article-title>Metal-triggered structural transformations, aggregation, and fibrillation of human <italic>α</italic>-synuclein: a possible molecular link between parkinson’s disease and heavy metal exposure</article-title>. <source>Journal of Biological Chemistry</source>, <volume>276</volume>(<issue>47</issue>):<fpage>44284</fpage>–<lpage>44296</lpage>.</mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><string-name><surname>Van der Perren</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Gelders</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Fenyi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bousset</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Brito</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Peelaerts</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Van den Haute</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Gentleman</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Melki</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Baekelandt</surname>, <given-names>V.</given-names></string-name> (<year>2020</year>). <article-title>The structural differences between patient-derived <italic>α</italic>-synuclein strains dictate characteristics of parkinson’s disease, multiple system atrophy and dementia with lewy bodies</article-title>. <source>Acta Neuropathol</source>, <volume>139</volume>(<issue>6</issue>):<fpage>977</fpage>–<lpage>1000</lpage>.</mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><string-name><surname>Watts</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Giles</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Oehler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Middleton</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Dexter</surname>, <given-names>D. T.</given-names></string-name>, <string-name><surname>Gentleman</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>DeArmond</surname>, <given-names>S. J.</given-names></string-name>, and <string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name> (<year>2013</year>). <article-title>Transmission of multiple system atrophy prions to transgenic mice</article-title>. <source>Proc Natl Acad Sci U S A</source>, <volume>110</volume>(<issue>48</issue>):<fpage>19555</fpage>–<lpage>60</lpage>.</mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><string-name><surname>Woerman</surname>, <given-names>A. L.</given-names></string-name>, <string-name><surname>Kazmi</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Patel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Aoyagi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Oehler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Widjaja</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Mordes</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Olson</surname>, <given-names>S. H.</given-names></string-name>, and <string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name> (<year>2018a</year>). <article-title>Familial parkinson’s point mutation abolishes multiple system atrophy prion replication</article-title>. <source>Proceedings of the National Academy of Sciences</source>, <volume>115</volume>(<issue>2</issue>):<fpage>409</fpage>–<lpage>414</lpage>.</mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><string-name><surname>Woerman</surname>, <given-names>A. L.</given-names></string-name>, <string-name><surname>Kazmi</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Patel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Freyman</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Oehler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Aoyagi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mordes</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Halliday</surname>, <given-names>G. M.</given-names></string-name>, <string-name><surname>Middleton</surname>, <given-names>L. T.</given-names></string-name>, <string-name><surname>Gentleman</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Olson</surname>, <given-names>S. H.</given-names></string-name>, and <string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name> (<year>2018b</year>). <article-title>Msa prions exhibit remarkable stability and resistance to inactivation</article-title>. <source>Acta Neuropathologica</source>, <volume>135</volume>(<issue>1</issue>):<fpage>49</fpage>–<lpage>63</lpage>.</mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><string-name><surname>Woerman</surname>, <given-names>A. L.</given-names></string-name>, <string-name><surname>Oehler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kazmi</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Halliday</surname>, <given-names>G. M.</given-names></string-name>, <string-name><surname>Middleton</surname>, <given-names>L. T.</given-names></string-name>, <string-name><surname>Gentleman</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Mordes</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Spina</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Grinberg</surname>, <given-names>L. T.</given-names></string-name>, <string-name><surname>Olson</surname>, <given-names>S. H.</given-names></string-name>, and <string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name> (<year>2019</year>). <article-title>Multiple system atrophy prions retain strain specificity after serial propagation in two different tg(snca*a53t) mouse lines</article-title>. <source>Acta Neuropathologica</source>, <volume>137</volume>(<issue>3</issue>):<fpage>437</fpage>–<lpage>454</lpage>.</mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><string-name><surname>Woerman</surname>, <given-names>A. L.</given-names></string-name>, <string-name><surname>Patel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kazmi</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Oehler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Mordes</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Olson</surname>, <given-names>S. H.</given-names></string-name>, and <string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name> (<year>2020</year>). <article-title>Kinetics of <italic>α</italic>-synuclein prions preceding neuropathological inclusions in multiple system atrophy</article-title>. <source>PLOS Pathogens</source>, <volume>16</volume>(<issue>2</issue>):<fpage>e1008222</fpage>.</mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><string-name><surname>Woerman</surname>, <given-names>A. L.</given-names></string-name>, <string-name><surname>Stöhr</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Aoyagi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Rampersaud</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Krejciova</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Watts</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Ohyama</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Patel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Widjaja</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Oehler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sanders</surname>, <given-names>D. W.</given-names></string-name>, <string-name><surname>Diamond</surname>, <given-names>M. I.</given-names></string-name>, <string-name><surname>Seeley</surname>, <given-names>W. W.</given-names></string-name>, <string-name><surname>Middleton</surname>, <given-names>L. T.</given-names></string-name>, <string-name><surname>Gentleman</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Mordes</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Südhof</surname>, <given-names>T. C.</given-names></string-name>, <string-name><surname>Giles</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Prusiner</surname>, <given-names>S. B.</given-names></string-name> (<year>2015</year>). <article-title>Propagation of prions causing synucleinopathies in cultured cells</article-title>. <source>Proc Natl Acad Sci U S A</source>, <volume>112</volume>(<issue>35</issue>):<fpage>E4949</fpage>–<lpage>58</lpage>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><string-name><surname>Yamasaki</surname>, <given-names>T. R.</given-names></string-name>, <string-name><surname>Holmes</surname>, <given-names>B. B.</given-names></string-name>, <string-name><surname>Furman</surname>, <given-names>J. L.</given-names></string-name>, <string-name><surname>Dhavale</surname>, <given-names>D. D.</given-names></string-name>, <string-name><surname>Su</surname>, <given-names>B. W.</given-names></string-name>, <string-name><surname>Song</surname>, <given-names>E. S.</given-names></string-name>, <string-name><surname>Cairns</surname>, <given-names>N. J.</given-names></string-name>, <string-name><surname>Kotzbauer</surname>, <given-names>P. T.</given-names></string-name>, and <string-name><surname>Diamond</surname>, <given-names>M. I.</given-names></string-name> (<year>2019</year>). <article-title>Parkinson’s disease and multiple system atrophy have distinct <italic>α</italic>-synuclein seed characteristics</article-title>. <source>J Biol Chem</source>, <volume>294</volume>(<issue>3</issue>):<fpage>1045</fpage>–<lpage>1058</lpage>.</mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="journal"><string-name><surname>Yang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Schweighauser</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Kotecha</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Murzin</surname>, <given-names>A. G.</given-names></string-name>, <string-name><surname>Garringer</surname>, <given-names>H. J.</given-names></string-name>, <string-name><surname>Cullinane</surname>, <given-names>P. W.</given-names></string-name>, <string-name><surname>Saito</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Foroud</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal> (<year>2022</year>). <article-title>Structures of <italic>α</italic>-synuclein filaments from human brains with lewy pathology</article-title>. <source>Nature</source>, <volume>610</volume>(<issue>7933</issue>):<fpage>791</fpage>–<lpage>795</lpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92775.1.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mistry</surname>
<given-names>Pramod</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Yale University</institution>
</institution-wrap>
<city>New Haven</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
</front-stub>
<body>
<p>Parkkinen et al. describe distinct biophysical profiles of brain-derived alpha-synuclein vs. in vitro-seeded synuclein fibrils. The findings are <bold>important</bold> and relevant to the emerging potential role of SAA as a biomarker of PD. The evidence is <bold>solid</bold>, using appropriate methodology and providing some support for the main claims with some limitations.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92775.1.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>SUMMARY:</p>
<p>Parkinson's disease (PD) and other synucleinopathies, including Parkinson's Disease Dementia (PDD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA), pose significant challenges for early diagnosis, as their clinical manifestations often emerge after substantial neurodegeneration has occurred. In this context, the Alpha-Synuclein Seeding Amplification Assay (SAA) has garnered considerable attention for its potential as a diagnostic tool, capable of detecting pathological forms of alpha-synuclein (αSyn) even before the onset of classical clinical symptoms and signs. The assay exploits αSyn's intrinsic property to convert healthy forms into pathological ones, subsequently amplifying these pathological forms for visualization. This study aims to investigate the efficacy of SAA in accurately identifying subtypes of synucleinopathies, including PD, PDD, DLB, and MSA. To achieve this, the results from the patient brain-derived αSyn SAA are compared with those obtained through conformational stability assays, immunolabeling, and electron microscopy. Study shows that brain-derived αSyn fibrils exhibit significant differences across various synucleinopathies in their conformation, biochemical profile and phosphorylation patterns. Importantly, the SAA method appears to fall short in capturing these distinctions.</p>
<p>The study's findings are highly relevant given the rapidly advancing landscape of utilizing the SAA for the diagnosis and differentiation of various forms of PD and synucleinopathies using patient biofluids. It is somewhat surprising that the authors primarily characterize SAA as a research tool without delving into its potential as a biomarker detection assay, especially in the context of the field's excitement about its diagnostic applications. Additionally, a missed opportunity lies in not referencing a recent study that employed SAA successfully to diagnose PD and subtype the condition using a vast sample size. To further strengthen the results, the inclusion of healthy control brains in the biochemical and immunostaining/immunoblot experiments would provide more robust comparisons. Overall, the authors have conducted their experiments diligently, and their study offers valuable insights that align with the ongoing efforts to enhance early diagnosis and subtype differentiation in the domain of synucleinopathies.</p>
<p>STRENGTH:</p>
<p>The strengths of this research article are indeed notable and contribute to the credibility and significance of the study:</p>
<p>Important Research Question: The study addresses a crucial question in the field of neurodegenerative diseases by evaluating the effectiveness of the αSyn SAA in diagnosing and differentiating synucleinopathies. This question is of significant clinical and scientific interest.</p>
<p>
Comprehensive Introduction: The article provides a thorough and well-structured introduction to the topic with an illustration, setting the stage for the research. It ensures that readers, including those unfamiliar with the subject matter, can grasp the context and significance of the study.</p>
<p>
Use of Patient Brain Tissue: The use of patient-derived brain tissue samples from various synucleinopathies, including PD, PDD, DLB, and MSA, enhances the clinical relevance and applicability of the findings.</p>
<p>
Replication and Statistical Significance: Conducting the experiments six times for each sample demonstrates the rigor of the study and the robustness of the results, and increases the confidence in the conclusions drawn.</p>
<p>
Clarity in Experimental Results and Discussion: The authors have presented the experimental results in a clear and understandable manner. I was personally impressed by images showing twisted and straight conformations of αSyn, as well as immunogold labeling for phosphorylation of αSyn, which aids in conveying the findings effectively to the readers. The results clearly show distinct differences in the characteristics of αSyn fibrils across different synucleinopathies. It also highlights the more aggressive seeding capacities and higher biochemical stability of αSyn in PDD and DLB patients, offering valuable insights into the pathophysiology of these conditions. The authors also clearly show that SAA fails in differentiating the disease types within the synucleinopathies.</p>
<p>
Clinical relevance: The study underscores the importance of considering complementary diagnostic methods alongside SAA for a more comprehensive understanding of synucleinopathy subtypes. The study might also play an important role in potential FDA approval of SAA as a diagnostic tool for synucleinopathies, especially for PD.</p>
<p>
These strengths collectively make the study a valuable contribution to the field of neurodegenerative diseases, shedding light on the limitations and potential applications of SAA in the diagnosis and differentiation of various synucleinopathies.</p>
<p>WEAKNESS:</p>
<p>While this study is overall robust, there are several aspects that could further enhance the quality and interpretation of the findings.</p>
<p>Clinical Data on Patient Brain Samples: The inclusion of specific details such as post-mortem intervals and the age at disease onset for patient brain samples would be valuable. These factors could significantly affect the quality of the tissues and their relevance to the study. Moreover, given the large variation in disease duration between PD and PDD, it's important to consider disease duration as a potential confounding factor, especially when concluding that PDD patients have a more severe form of synucleinopathy compared to PD.</p>
<p>
Inclusion of Healthy Controls in Multiple Tests: Given the importance of healthy controls in scientific studies, especially those involving human brain samples, the authors could consider using healthy controls in more tests to strengthen the robustness of the findings. Expanding the use of healthy controls in biochemical profiling and phosphorylation profiles would provide a better basis for comparison and clarify the significance of results in a disease context.</p>
<p>
This will help the authors to elaborate on the interpretation of results, for example, in Figure 3, where the authors claim that PD brains show mostly monomeric αSyn forms (line 119 and 120, and also in 222 and 223). Whether it implies the absence of alpha-syn pathology in PD brains? If there are differences from healthy controls? What are these low molecular weight bands (&lt;15kD) (line 125-126) and whether they are also present in healthy controls? Also, we do not have a perfect pS129-specific (anti-p𝛼Syn) antibody. They are known for non-specific labeling. Investigating the phosphorylation levels in healthy controls and comparing them to PD brains, especially considering the predominance of monomeric (healthy αSyn?) in PD brains, would help clarify the observed changes.</p>
<p>
Age of Healthy Controls: Providing information about the age at death for healthy controls is crucial, as age can impact the accumulation of αSyn. Also include if the brain samples were age-matched, or analyses were age-adjusted.</p>
<p>
Braak Staging Discrepancy: The study reports the same Braak staging for both PD and PDD, despite the significant difference in disease duration. Maybe other reviewers with clinical experience might have a better take on this. This observation merits discussion in the paper, allowing readers to better understand the implications of this finding.</p>
<p>
Citation of Relevant Studies: The paper should consider citing and discussing a recent celebrated study on PD biomarkers that used thousands of cerebrospinal fluid (CSF) samples from different PD patient cohorts to demonstrate the effectiveness of SAA as a biochemical assay for diagnosing PD and its subtypes (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1474-4422(23)00109-6">https://doi.org/10.1016/S1474-4422(23)00109-6</ext-link>).</p>
<p>
In summary, these suggestions aim to enhance the study's quality and the clarity of its findings, ultimately contributing to a more comprehensive understanding of synucleinopathies and the diagnostic potential of SAA.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92775.1.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Most neurodegenerative diseases are characterized by the self-templated misfolding of a particular protein in a manner that enables progressive spread throughout the central nervous system. In diseases including Parkinson's disease (PD) and multiple system atrophy (MSA), the protein alpha-synuclein misfolds into unique shapes, or strains, which use this self-replicating mechanism to encode disease-specific information. Previous research suggests that a major contributor to the lack of successful clinical trials across neurodegenerative diseases is the lack of disease-relevant strains used in preclinical testing. While MSA patient samples are known to replicate efficiently in cell and mouse models of disease, Lewy body disease (LBD) patient samples do not. To overcome this obstacle, the seeding amplification assay (SAA) uses recombinant alpha-synuclein to amplify the misfolded protein structure present in a human patient sample. The resulting fibrils are then widely used by many laboratories as a model of PD. In this manuscript, Lee et al., set out to compare the strain properties of alpha-synuclein fibrils isolated from LBD and MSA patient samples with the resulting amplified fibrils following SAA. Using orthogonal biochemical and structural approaches to strengthen their analyses, the authors report that the SAA-amplified fibrils do not recapitulate the disease-relevant strains present in the patient samples. Moreover, their data suggest that regardless of which strain is used to seed the SAA reaction, the same strain is generated. These results clearly demonstrate that the SAA-amplified material is not disease-relevant. SAA fibrils are broadly used in academic and pharmaceutical laboratories. They are used in ongoing drug discovery efforts and recombinant fibrils broadly inform much of what is known about alpha-synuclein strain biology in LBD patients. The implications of the reported work are, therefore, expansive. These findings add to the growing ledger of reasons that the use of SAA fibrils in research should be halted until improved methods for amplification with high fidelity are developed.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92775.1.sa0</article-id>
<title-group>
<article-title>Reviewer #3 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>This interesting manuscript presents a comparison of biophysical properties, TEM appearances, and phosphorylation patterns of brain-derived synuclein fibrils from 3 subjects each with Parkinson Disease (PD), Parkinson Disease with Dementia (PDD), Dementia with Lewy bodies (DLB) and Multiple System Atrophy (MSA), the effects of studying these brain-derived fibrils in a Seeding Aggregation Assay (SAA), and a comparison of the seeded and resultant fibers. The results are not unexpected.</p>
<p>Strengths:</p>
<p>The work explores an important question. Namely, what is the fidelity of synuclein fibrils produced during an SAA reaction to the starting material if that material has been extracted from the brains of deceased patients with synucleinopathies.</p>
<p>Weaknesses:</p>
<p>The work suffers from several methodological flaws</p>
<p>The experiments are missing two important controls. 1) what to fibrils generated by different in vitro fibril preparations made from recombinant synclein protein look like; and 2) the use of CSF from the same patients whose brain tissue was used to assess whether CSF and brain seeds look and behave identically. The latter is perhaps the most important question of all - namely how representative are CSF seeds of what is going on in patients' brains?</p>
<p>In their discussion the authors do not comment on the obvious differences in the conditions leading to the formation of seeds in the brain and in the artificial conditions of the seeding assay. Why should the two sets of conditions be expected to yield similar morphologies, especially since the extracted fibrils are subjected to harsh conditions for solubilization and re-suspension.</p>
<p>Finally, the key experiment was not performed - would the resultant seeds from SAA preparations from the different nosological entities produce different pathologies when injected into animal brains? But perhaps this is the subject of a future manuscript.</p>
<p>Furthermore, the authors comment on phosphorylation patterns, stating that the resultant seeds are less heavy phosphorylated than the original material. Again, this should not be surprising, since the SAA assay conditions are not known to contain the enzymes necessary to phosphorylate synuclein. The discussion of PTMs is limited to pS-129 phosphorylation. What about other PTMs? How does the pattern of PTMs affect the seeding pattern.</p>
<p>Lastly, the manuscript contains no data on how the diagnostic categories were assigned at autopsy. This information should be included in the supplementary material.</p>
</body>
</sub-article>
</article>